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NOVEL DRUG DELIVERY SYSTEM 
Novel drug delivery system aims to provide a therapeutic amount of drug to the 
appropriate site in the body to accomplish promptly and then maintain the desired drug 
concentration. The drug delivery system should deliver the drug at a rate controlled by the 
necessity of the body over a specified term of treatment. 
The two important aspects of idealized drug delivery are as follows; 
 Spatial drug delivery: Targeting a drug to a particular organ or tissue. 
 Temporal drug delivery: the drug delivery rate to a target tissue is controlled. 
Novel drug delivery systems are designed to achieve a continuous delivery of drugs 
at predictable and reproducible kinetics over an extended period of time in the circulation. The 
potential advantages of this concept include minimization of drug related side effects due to 
controlled therapeutic blood levels instead of oscillating blood levels, improved patient 
compliance due to reduced frequency of dosing and the reduction of the total dose of drug 
administered. Hence, the combination of both sustained release and control release properties 
in a delivery system would further enhance therapeutic efficacy.4 
A number of novel drug delivery systems has emerged encompassing various routes of 
administration, to achieve controlled and targeted drug delivery. Encapsulation of the drug in 
vesicular structure is one such system, which can be predicted to prolong the existence of the 
drug in systemic circulation and reduce the toxicity if selective uptake can be achieved. 
Consequently a number of vesicular drug delivery systems such as liposomes, niosomes, 
transferosomes and pharmacosomes were developed. Advances have since been made in the 
area of vesicular drug delivery, leading to the development of this system that allow drug 
targeting and sustained or controlled release of conventional drug medicines.10 
For many decades treatment of an acute disease or a chronic illness has been mostly 
accomplished by delivery of drugs to patients using various pharmaceutical conventional 
dosage forms. Even today conventional drug delivery system occupies most of the part in a 
prescription as well as drug store. This type of drug delivery system is known to provide a 
prompt release of drug. But to achieve as well as to maintain the drug concentration within the 
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therapeutically effective range needed for treatment, it is often necessary to take this type of 
drug delivery system several times a day. This results in significant fluctuations in drug level.5 
DISADVANTAGES OF CONVENTIONAL DOSAGE FORMS52 
i. Drugs with short half- life require frequent administration, which increases chances of 
missing the dose of a drug leading to poor patient compliance. 
ii. A typical peak- valley plasma concentration- time profile is obtained which makes 
attainment of steady state condition very difficult. 
iii. The unavoidable fluctuations in the drug concentration may lead to under- medication 
or over- medication as the Css values fall or rise beyond the therapeutic range which 
may lead to adverse effects of the drug. 
iv. Drug accumulation may occur in case of the frequent administration of the drugs. 
To overcome the above drawbacks, drug delivery systems capable of controlling the 
rate of drug delivery, sustaining the duration of therapeutic action and/ or targeting the drug to 
a particular tissue was developed.  
The novel drug delivery systems are diversely referred to as “controlled release”, 
“sustained release”, “zero- order”, “reservoir”, “monolithic”, “membrane- controlled”, 
“smart”, “stealth” etc. some of these common terms are defined as follows:1 
 Prolonged/ sustained release: the delivery system prolongs therapeutic blood or tissue 
levels of the drug for an extended period of time. 
 Zero order release: the drug release does not vary with time; thus the delivery system 
maintains a (relatively) constant effective drug level in the body for prolonged periods. 
 Variable release: the delivery system provides drug input at a variable rate, to match, for 
example endogenous circadian rhythms, or to mimic natural biorhythms. 
 Bio- responsive release: the system modulates drug release in response to a biological 
stimulus (e.g. blood glucose levels triggering the release of insulin from a drug delivery 
device) 
 Modulated/ self-regulated release: the system delivers the necessary amount of drug 
under the control of the patient.  
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 Rate- controlled release: the system delivers the drug at some pre- determined rate, 
whether systemically or locally, for a specific period of time. 
 Targeted- drug delivery: the delivery system achieves site- specific drug delivery. 
 Temporal- drug delivery: the control of delivery to produce an effect in a desired time- 
related manner. 
 Spatial- drug delivery: the delivery of a drug to a specific region of the body (thus this 
term encompasses both route of administration and drug distribution). 
 Bioavailability: the rate and extent at which a drug is taken up into the body. 
 Repeat action: individual dose is released fairly soon after administration and second or 
third doses are subsequently released at intermittent intervals.1 
CLASSIFICATION OF CONTROLLED DRUG DELIVERY SYSTEMS (CDDS).5 
Controlled drug delivery systems can be classified as 
 Rate-preprogrammed drug delivery system. 
 Activation-modulated drug delivery system. 
 Feed-back regulated drug delivery system. 
 Site-targeting drug delivery system. 
TARGETED/ SITE- SPECIFIC DRUG DELIVERY SYSTEM 
While rate- controlled systems can deliver the drug at a predetermined rate, they are 
generally unable to control the fate of the drug, once it enters the body. The concept of 
designing specified delivery system to achieve selective drug targeting has been originated 
from the perception of Paul Ehrlich, who proposed drug delivery to be as a “Magic 
bullet”(Paul Ehrlich, 1902) describing targeted drug delivery as an event where, a drug-carrier 
complex/conjugate, delivers drug(s) exclusively to the preselected target cells in a specific 
manner.6  
Targeted drug delivery system refers to systems that place the drug at or near the 
receptor site or site of action. Targeted drug delivery implies selective and effective 
localization of drug into the target(s) at therapeutic concentrations with limited access to target 
sites.6 
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Site- specific drug delivery is desirable in therapeutics, in order to improve:1 
 Drug safety, as toxic side- effects caused by drug action at non- target sites are minimized. 
 Drug efficacy, as the drug is concentrated at the site of action rather than being dispersed 
throughout the body. 
 Patient compliance, as increased safety and efficacy should make therapy more acceptable 
and thus improve compliance.1 
Technologies for drug targeting are concerned with delivering drugs to specific targets 
in the body and also to protect drugs from degradation and premature elimination. They include 
the use of 
 Soluble carriers, such as monoclonal antibodies, dextrans, soluble synthetic polymers 
 Particulate carriers, such as liposomes, niosomes, micro- and nano- particles, 
microspheres 
 Target- specific recognition moieties, such as monoclonal antibodies, carbohydrates and 
lectins. 
Recent advances in biological and chemical sciences have led to the development of 
various “smart” technologies to ensure more effective drug delivery and targeting of drugs to 
specific sites within the body. Such approaches include the use of: 
 Antibody- directed enzyme/ prodrug therapy (ADEPT)52 
 Virus- directed prodrug/ enzyme therapy (VDEPT) 
 Chemical drug delivery systems 
DRUG DELIVERY CARRIERS2, 6 
A Carrier is one of the most important entities essentially required for successful 
transportation of the loaded drug(s). they are drug vectors, which sequester, transport and retain 
drug en route, while elute or deliver it within or in the vicinity of target.6 Colloidal drug carrier 
systems such as micellar solutions, vesicle and liquid crystal dispersions, as well as 
nanoparticle dispersions consisting of small particles of 10–400 nm diameter show great 
promise as drug delivery systems. When developing these formulations, the goal is to obtain 
systems with optimized drug loading and release properties, long shelf-life and low toxicity. 
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The incorporated drug participates in the microstructure of the system, and may even influence 
it due to molecular interactions, especially if the drug possess amphiphilic and/or mesogenic 
properties.2 
 
Figure 1 Pharmaceutical carriers2 
An ideal carrier engineered as a targetable device should have the following features: 
 It must be able to cross anatomical barriers and in case of tumour chemotherapy, tumour 
vasculature. 
 It must be recognized specifically and selectively by the target cells and must maintain the 
avidity and specificity of the surface ligands. 
 The linkage of the drug and the directing unit (ligand) should be stable in plasma, interstitial 
and other bio-fluids. 
 Carrier should be non-toxic, non-immunogenic and biodegradable particulate or 
macromolecule and after recognition, and internalization, the carrier system shoud release 
the drug moiety inside the target organs, tissues or cells. 
 The bio-modules used for carrier navigation  and site recognition should not be ubiquitous 
otherwise it may cross over the sites, defeating the concept of targeting.6 
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LEVELS OF DRUG TARGETING6 
The various approaches of vectoring the drug to the target site can be broadly classified as: 
 Passive targeting 
 Inverse targeting 
 Active targeting (Ligand mediated targeting and Physical targeting). 
 Dual targeting 
 Double targeting 
 Combination targeting 
PASSIVE TARGETING6 
Systems that target the systemic circulation are generally characterized as “passive” delivery 
systems (i.e. targeting occurs because of the body’s natural response to the physicochemical 
characteristics of the drug or drug-carrier system. It is a sort of passive process that utilizes the 
natural course of (attributed to inherent characteristics) bio-distribution of the carrier system, 
through which, it eventually accumulate in the organ compartment(s) of body. 
 The ability of some colloids to be taken up by the RES especially in liver and spleen has 
made them as ideal vectors for passive targeting of drugs to these compartments. Passive 
capture of colloidal carriers by macrophage offers therapeutic opportunities for the delivery of 
anti-infectives for disease conditions that involve macrophage cells of the reticuloendothelial 
system (RES) e.g., leishmaniasis, brucellosis and candidiasis. This category of targetable 
devices includes drug bearing bilayer vesicular systems as well as circular carriers of micron 
or sub-micron size.  
The passive targetabiity of microparticulate drug carriers is due to the recognition of these 
particulates either in the intact or in the opsonized form, by the phagocytic cells of the RES 
and this sensing behavior is exploited to target MPS associated disease cell lines. 
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INVERSE TARGETING6 
It is essentially based on successful attempts to avoid passive uptake of colloidal carriers by 
reticulo-endothelial system (RES). This effectively leads to the reversion of bio-distribution 
trend of the carrier and hence, the process is referred to as “Inverse targeting”. 
 One strategy applied to achieve inverse targeting is to suppress the function of RES by a 
pre-injection of a large amount of blank colloidal carriers or macromolecules like dextran- 
sulphate. This approach leads to saturation of RES and suppression of defense mechanism. 
This type of targeting is an effective approach to target drug(s) to non-RES organs. 
ACTIVE TARGETING 120 
In this approach carrier system bearing drug reaches to specific site on the basis of modification 
made on its surface rather than natural uptake by RES. Surface modification technique include 
coating of surface with either a bio-adhesive, nonionic surfactant or specific cell or tissue 
antibodies (i.e. monoclonal antibodies) or by albumin protein. 
First order targeting: It involves distribution of drug carrier system to capillary bed of target 
site or organ. For example lymphatics, peritoneal cavity, pleural cavity, cerebral ventricles, 
etc. 
Second order targeting: it involves delivery of drug to special cells such as tumor cells or 
kupffer cells in liver. 
Third order targeting: Third order targeting means intracellular localization of carrier bearing 
drug by the process of endocytosis or via receptor based ligand mediated entry of drug carrier 
system, where lysosomal degradation of drug complex causes release of drug or gene delivery 
to nucleolus. 
Ligand mediated targeting:- All the drug carrier system can become functional when they 
are attached with biologically relevant molecular ligand including antibodies, polypeptides, 
oligosaccharides, viral proteins and fusogenic residues. These types of engineered carrier 
selectively make the drug available to the cell or group of cells generally referred as target. In 
ligand mediated active targeting, reaction of a ligand to corresponding receptor enhances the 
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uptake of the entire drug delivery system into the cell. An example of this approach is folate 
receptor targeting.  
Physical Targeting:-In this type of targeting some characteristics of environment changes like 
pH, temperature, light intensity, electric field, ionic strength, small and even specific stimuli 
like glucose concentration are used to localize the drug carrier to predetermined site. This 
approach was found exceptional for tumor targeting as well as cytosolic delivery of entrapped 
drug or genetic material. 
DUAL TARGETING6 
This type of targeting employs carrier molecules, which have their own intrinsic anti-viral 
effect thus synergies the antiviral effect of the loaded active drug. Based on this approach, drug 
conjugates can be prepared with fortified activity profile against the viral replication. A major 
advantage is that the virus replication process can be attacked at multiple points, excluding the 
possibilities of resistant viral strain development. 
DOUBLE TARGETING6 
In this type, if spatial targeting is combined with temporal control release results in an 
improved therapeutic index by the following effects; 
 If drug release or activation is occurred locally at therapeutic sites, selectivity is 
increased by multiplication of the spatial selectivity with the local release/activation. 
 The improvement in the therapeutic index by a combination of a spatially selective 
delivery and a preferable release pattern for a drug, such as zero order release for a 
longer time period of the drugs. 
COMBINATION TARGETING6 
These targeting systems are equipped with carriers, polymers and homing devices of 
molecular specificity that could provide a direct approach to target site. Modification of 
proteins and peptides with natural polymers may alter their physical characteristics and favor 
targeting the specific compartments, organs or their tissues within the vasculature.          
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VESICULAR DRUG DELI VERY SYSTEMS 7 
The vesicular systems are highly ordered assemblies of one or several concentric lipid 
bilayers formed, when certain amphiphilic building blocks are confronted with water. Vesicles 
can be formed from a diverse range of amphiphilic building blocks. Biologic origin of these 
vesicles was first reported in 1965 by ‘Bingham’ and has been given the name Bingham bodies. 
Now a days, vesicles as a carrier system have become the vehicle of choice in drug 
delivery and lipid vesicles were found to be of value in immunology, membrane biology and 
diagnostic technique and most recently in genetic engineering. Vesicular delivery system 
provides an efficient method for delivery to the site of infection, leading to reduction of drug 
toxicity with no adverse effects. Vesicular drug delivery reduces the cost of therapy by 
improved bioavailability of medication, especially in case of poorly soluble drugs. They can 
incorporate both by hydrophilic and lipophilic drugs. Different novel approaches used for 
delivering the drugs by vesicular system include liposomes, niosomes, sphingosomes, 
transferosomes and pharmacosomes. 
Encapsulation of a drug in vesicular structures can be predicted to prolong the existence 
of the drug in systemic circulation, and perhaps, reduces the toxicity, if selective uptake can 
be achieved. Lipid vesicles are one type of many experimental models of bio-membranes 
which evolved successfully, as vehicles for controlled delivery. For the treatment of 
intracellular infections, conventional chemotherapy is not effective, due to limited permeation 
of drugs into cells. This can overcome by the use of vesicular drug delivery systems.7 
ADVANTAGES OF VESICULAR DRUG DELIVERY7 
1. Prolong the existence of the drug in systemic circulation, and perhaps, reduces the 
toxicity if selective uptake can be achieved due to the delivery of drug directly to the 
site of infection. 
2. Improves the bioavailability especially in the case of poorly soluble drugs. 
3. Both hydrophilic and lipophilic drugs can be incorporated. 
4. Delays elimination of rapidly metabolizable drugs and thus function as sustained 
release systems.7 
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These vesicular systems are accompanied with some problems like drug carriers and 
externally triggered (eg., temperature, pH, or magnetic sensitive) carriers load drugs passively, 
which may lead to low drug loading efficiency and drug leakage in preparation, preservation 
and transport in- vivo.7Need of intensive sonication, lead to leakages of drug during storage. 
Thus the major problem of their stability acts as a barrier and thus limiting their use.8 
The targeted vesicles are classified on the basis of their composition as9 
 Lipoidal bio-carriers. 
 Liposomes  
 Emulsomes  
 Enzymosomes 
 Ethosomes 
 Sphingosomes 
 Transferosomes 
 Pharmacosomes 
 Virosomes  
 Non- lipoidal biocarriers 
i. Niosomes 
ii. Bilosomes 
iii. Aquasomes  
LIPOSOMES10 
Liposomes or lipid based vesicles are microscopic (unilamellar or multilamellar) 
vesicles that are formed as a result of self-assembly of phospholipids in an aqueous media 
resulting in closed bi-layered structures. The assembly into closed bi-layered structures is a 
spontaneous process and usually needs some input of energy in the form of physical agitation, 
sonication, heat etc. Since lipid bi-layered membrane encloses an aqueous core, both water and 
lipid soluble drugs can be successfully entrapped into the liposomes. The lipid soluble or 
lipophilic drugs get entrapped within the bi-layered membrane whereas water soluble or 
hydrophilic drugs get entrapped in the central aqueous core of the vesicles.7 For drug delivery 
applications, liposomes are usually uni-lamellar and range in diameter from about 50 – 150 
nm.  
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Liposomes can be used for both oral as well as topical drug targeting. They act by the 
following mechanisms. They attach to cellular membrane and appear to fuse with them, 
releasing their content into the cell. Sometimes, they are taken up by the cell and their 
phospolipids are incorporated into the cell membrane by which the drug trapped inside is 
released.9 
EMULSOME11 
Emulsomes are a new generation of colloidal carrier systems in which internal core is 
made of fats and triglycerides which is stabilized by high concentration of lecithin in the form 
of o/w emulsion. Emulsomes have the characteristics of both liposomes and emulsions. The 
solidified or semi-solidified internal oil core provides a better opportunity to load lipophilic 
drugs in high concentrations. Simultaneously, a prolonged controlled release can also be 
expected and the ability to encapsulate water-soluble medicaments in the aqueous 
compartments of surrounding phospholipid layers. The solvent free and surfactant free 
emulsomes technology have demonstrated high drug en-capsulation capacity for water 
insoluble antifungal and anticancer drugs showing enhanced drug delivery and improved 
preclinical efficacy for parenteral routes. 
ENZYMOSOME10 
The structure in which an enzyme is enclosed in a liposome is called an enzymosome. 
These are liposomal constructs engineered to provide a mini bio-environment in which 
enzymes are covalently immobilized or coupled to the surface of the liposomes thereby 
targeting the drugs to the tumor cells. 
ETHOSOMES10 
Ethosomes are non-invasive delivery carriers that enable drugs to reach the deep skin 
layers and/or the systemic circulation. These are soft, malleable vesicles tailored for enhanced 
delivery of active agents. They are composed mainly of phospholipids (phosphatidylcholine, 
phosphatidylserine, phosphatidic acid), high concentration of ethanol and water. The high 
concentration of ethanol makes the ethosomes unique, as ethanol is known for its disturbance 
of skin lipid bilayer organization therefore, when integrated into a vesicle membrane it gives 
that vesicle the ability to penetrate the stratum corneum. Also because of their high ethanol 
concentration, the lipid membrane is packed less tightly than conventional vesicles but has 
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equivalent stability, allowing a more malleable structure and improves drug distribution ability 
in stratum corneum. 
SPHINGOSOMES10 
Sphingosomes are concentric, bi-layered vesicle in which an aqueous volume is 
enclosed by a membranous lipid bilayer mainly composed of natural or synthetic sphingolipids. 
Sphingosomes are comprised of sphingolipids and cholesterol, an interior aqueous 
environment having pH less than that of exterior. The drug is encapsulated inside the lipid 
bilayer and is delivered to the host at a predetermined rate thereby improving the efficacy, 
increasing the circulation time and reducing the toxicity. Sphingosomes can be utilized for 
therapeutic, cosmetic and diagnostic purpose for the delivery of active to the target site or 
organ. They can be administered by variety of routes like oral, parenteral, inhalation, 
transdermal etc. Sphingolipid present in the sphingosomes offer several advantages to these 
vesicular systems for targeting both by passive and active targeting mechanism. 
TRANSFEROSOMES10 
Transferosomes are specially optimized, ultradeformable (ultraflexible) lipid supra-
molecular aggregates, which are able to penetrate the mammalian skin intact. Each 
transferosome consists of at least one inner aqueous compartment, which is surrounded by a 
lipid bilayer with specially tailored properties, due to the incorporation of "edge activators" 
into the vesicular membrane. Surfactants such as sodium cholate, sodium deoxy-cholate, Span 
80 and Tween 80, have been used as edge activators. It was suggested that transferosomes 
could respond to external stress by rapid shape transformations requiring low energy. These 
novel carriers are applied in the form of semi-dilute suspension, without occlusion. Due to their 
deformability, transferosomes are good candidates for the non-invasive delivery of small, 
medium and large sized drugs. They have been used as drug carriers for a range of small 
molecules, peptides, proteins and vaccines, both in- vitro and in- vivo.  
Materials commonly used for the preparation of transferosomes are phospholipids 
(soya phosphatidyl choline, egg phosphatidyl choline), surfactant (tween 80, sodium cholate) 
for providing flexibility, alcohol (ethanol, methanol) as a solvent, dye for confocal scanning 
laser microscopy (CSLM) and buffering agent (saline phosphate buffer pH 7.4), as a hydrating 
medium. 
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PHARMACOSOMES7 
These are defined as colloidal dispersions of drugs covalently bound to lipids and may 
exist as ultrafine vesicular, micellar or hexagonal aggregates, depending on the chemical 
structure of drug-lipid complex. The pro-drug conjoins hydrophilic and lipophilic properties 
and therefore acquires amphiphilic characters and was found to reduce interfacial tension and 
thus at higher concentrations exhibits mesomorphic behavior. Because the system is formed 
by linking a drug (pharmakon) to a carrier (soma), they are called pharmacosomes. 
Pharmacosomes bearing unique advantages over liposome and niosome vesicles have come up 
as potential alternative to conventional vesicles. 
VIROSOMES11 
Virosomes are reconstituted viral envelopes including membrane lipids and viral spike 
glycoproteins but devoid of viral genetic material. The external surface of the virosome 
resembles that of a virus particle with spike proteins protruding from the membrane but their 
interior compartment is empty. Virosomes were first prepared with inserted purified influenza 
spike proteins into preformed liposomes. Thereafter a range of viral envelopes have been 
reconstituted including those of Sendai virus, Semliki Forest Virus (SFV), Vesicular Stomatitis 
Virus (VSV) and Sindbis virus. Because virosomes display viral envelope glycoproteins which 
in their native conformation stimulate humoral responses, they are highly effective as vaccine 
antigens and adjuvants. 
NIOSOMES7 
Niosomes are a novel drug delivery system, in which the medication is encapsulated in 
a vesicle. The vesicle is composed of a bilayer of non-ionic surface active agents and hence 
the name niosomes. The niosomes are very small, and microscopic in size. Their size lies in 
the nano-metric scale. Niosomes are non-ionic surfactant vesicles obtained on hydration of 
synthetic nonionic surfactants, with or without incorporation of cholesterol or other lipids. 
They are vesicular systems similar to liposomes that can be used as carriers of amphiphilic and 
lipophilic drugs.  Although structurally similar to liposomes, they offer several advantages over 
them. 
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COLLOIDOSOMES10 
Colloidosomes are the hollow shell microcapsules consisting of coagulated or fused 
particles at interface of emulsion droplets. Colloidosomes have exciting potential applications 
in controlled release of drugs, proteins, vitamins as well as in cosmetics and food supplements. 
Colloidosomes have a great encapsulation efficacy with a wide control over size, permeability, 
mechanical strength and compatibility. Colloidosomes assemble polymer latex, colloidal 
particles into shells around water-in-oil emulsion drops followed by partial fusion of shell and 
centrifugal transfer into water to yield stable capsules in which the shell permeability can be 
controlled by adjustment of partial fusion conditions. Hairy colloidosomes whose shell consists 
of micro-rod particles, are designed and fabricated novel colloidosome capsules that consist of 
aqueous gel core and shells of polymeric micro-rods. This has been achieved by templating 
water-in-oil emulsions stabilized by rod like particles followed by gelling of the aqueous phase, 
dissolution of oil phase in ethanol and re-dispersion of obtained colloidosome microcapsules 
in water. 
HERBOSOMES10 
The term "herbo" means plant, while "some" means cell-like. Over the past century, 
phyto- chemical and phyto-pharmacological sciences established the compositions, biological 
activities and health promoting benefits of numerous botanical products. Most of the 
biologically active constituents of plants are polar or water soluble molecules. However, water 
soluble phyto-constituents (like flavonoids, tannins, glycosidic aglycones etc) are poorly 
absorbed either due to their large moleculer size which cannot be absorbed by passive 
diffusion, or due to their poor lipid solubility, severely limiting their ability to pass across the 
lipid rich biological membranes, resulting in poor bioavailability. Phyto-medicines, complex 
chemical mixtures prepared from plants, have been used for health maintenance since ancient 
times. But many phyto-medicines are limited in their effectiveness because they are poorly 
absorbed when taken by mouth. Herbosomes are also often known as phyto-somes. Molecular 
layer consisting of PC and other phospholipids provides a continuous matrix into which the 
proteins insert. 
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CUBOSOMES10 
Bicontinuous cubic liquid crystalline materials are active ingredients because they give 
the unique structural ends to controlled release applications. Amphiphilic molecules form bi-
continuous water and oil channels, where “bi-continuous” refers to two distinct (continuous, 
but non-intersecting) hydrophilic regions separated by the bilayer. Cubosomes are discrete, sub 
micron, nanostructured particles of bicontinuous cubic liquid crystalline phase. Cubosomes 
possess the same microstructure as the parent cubic phase but have much larger specific surface 
area and their dispersions have much lower viscosity than the bulk cubic phase. The ability of 
cubic phases to exist as discrete dispersed colloidal particles or cubosomes is perhaps the most 
intriguing. Whereas most concentrated surfactants that form cubic liquid crystals lose these 
phases to micelle formation at high dilutions, a few surfactants have optimal water insolubility. 
Their cubic phases exist in equilibrium with excess water and can be dispersed to form 
cubosomes. 
LAYEROSOMES10 
The layer-by-layer coating concept is one of the strategies used for the preparation or 
the stabilization of nanosystems. The layersomes are conventional liposomes coated with one 
or multiple layers of biocompatible polyelectrolytes in order to stabilize their structure. The 
formulation strategy is based on an alternative coating procedure of positive poly (lysine) 
(pLL) and negative poly (glutamic acid) (pGA) polypeptides on initially charged small uni-
lamellar liposomes. Oral administration or their incorporation in biomaterials is among 
potential fields of application. 
UFASOMES10 
The fatty acid vesicles are named "ufasomes," ufosomes are unsaturated fatty acid 
liposomes. Fatty acid vesicles are colloidal suspensions of closed lipid bilayers that are 
composed of fatty acids and their ionized species (soap). They are observed in a small region 
within the fatty acid-soap-water ternary phase diagram above the chain melting temperature 
(Tm) of the corresponding fatty acid-soap mixture. Fatty acid vesicles always contain two 
types of amphiphiles, the non-ionized neutral form and the ionized form (the negatively 
charged soap). The ratio of non- ionized neutral form and the ionized form is critical for the 
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vesicle stability. Fatty acid vesicles are actually mixed "fatty acid/soap vesicles". Ufasome 
membranes are much more stabilized in comparison to liposomes. 
CRYPTOSOMES11 
Stealth liposomes, also known as immune-liposomes or cryptosomes are liposomes that 
evade detection in an immune system. Stealth liposomes or cryptosomes are designed to 
circulate for longer periods of time in- vivo, but they are different from "long-circulating 
liposomes". Stealth liposomes use polyethylene glycol (PEG) as a steric stabilizer. The 
properties of the stealth liposome depend on the way PEG is linked to the lipids. It is important 
to note that stealth liposomes are not fully inert vesicles; they can eventually become detected 
by the immune system. It could be used for slow release of drug or for imaging purposes. 
Incorporation of polymers, such as polyethylene glycol-lipid derivatives, or glycolipids into 
liposomes results in sterically stabilized liposomes which have several advantages over 
liposome formulations traditionally used in the past, including reduced recognition and uptake 
by macrophages, extended circulation half-lives, targeted drug delivery dose-independent 
pharmacokinetics, and increased uptake in- vivo by solid tumors, breast cancer. 
ULTRASOMES11 
Ultrasomes are specialized liposomes encapsulating an endonuclease enzyme extracted 
from Micrococcus luteus. Endonuclease recognizes ultra violet (UV) damage and is reported 
to accelerate its repair four-folds. Ultrasomes also protect the immune system by repairing UV-
DNA damage and reducing the expression of tumor necrosis factor (TNF-α), interleukins (IL-
1, IL-6 and IL-8). They stimulate the production of melanin by melanocytes in the tanning 
response following UV exposure and are used in cosmeceuticals and anti-aging formulations. 
PHOTOSOMES11 
These are artificial spherical submicroscopic vesicles with diameter between 25 and 
5000 nm. Photosomes are composed of amphiphilic molecules with core that consists of an 
aqueous cavity, which is encapsulated by one or more bimolecular phospholipid sheets 
separated from each other by aqueous layers. Photosomes contain the enzyme photolysase 
encapsulated in a liposome structure and are incorporated in sun-care product to protect the 
sun exposed skin by releasing a photo-reactivating enzyme extracted from a marine plant, 
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Anacystis nidulans. This enzyme can be activated by light and can work during the day to 
support the skin deoxyribonucleic acid (DNA) repair process.  
Combined with ultrasomes, they constitute the "intelligent" DNA repair system and are 
the most widely used in cosmetic delivery systems and photodynamic therapy. 
GENOSOMES11 
Genosomes are complex of genetic material like DNA and suitable lipid. They are also 
known as lipoplexes that are used to deliver genes. They are artificial macromolecular 
complexes for functional gene transfer. Cationic lipids are most suitable for this delivery 
system because they possess high biodegradability and stability in the blood stream. Mostly 
DNA-cationic liposome complexes were used to translocate DNA across cellular membranes 
in- vivo, because interaction between DNA-lipid membranes has proved crucial to the 
understanding of the colloidal state of the genosomes. These DNA lipid complexes could be 
later aggregated into higher order assemblies, creating stacked lipid-DNA multilayers, for 
generating more protection. 
VESOSOME11 
Vesosomes are multi-compartment structures which has distinct inner compartments 
separated from the external membrane. Each compartment of vesosome can encapsulate 
different materials and have different bilayer composition. Vesosome could entrap both 
colloidal particles and bio-logical macromolecules relatively efficiently. While small 
molecules are released from uni-lamellar liposomes in minutes, they are retained in vesosomes 
from hours to days, even though the liposomes and vesosomes have the same bilayer 
composition and size. Vesosomes are formed by adding ethanol to a variety of saturated 
phospholipids. At temperatures below the gel-liquid crystalline transition, Tm, the inter 
digitated lipid-ethanol sheets are rigid and flat; when the temperature is raised above Tm, the 
sheets become flexible and close on themselves and the surrounding solution to form closed 
compartments. 
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SUBTILOSOMES11 
Subtilosomes are prepared from phospholipids isolated from Bacillus subtilis. They are 
novel potential carrier system used in drug delivery. Cardiolipin and phosphatidyl glycerol are 
abundant in B. subtilis. 
ESCHERIOSOMES11 
These are lipoidal vesicles, prepared from polar lipids extracted from Escherichia coli. 
Majorly phosphatidyl ethanolamine, cardiolipin, and phosphatidyl glycerol are classes of 
phospholipid, present in E. coli. Escheriosomes encapsulated antigen elicit strong humoral 
immune response in immunized animals, in general, escheriosomes are considered as potential 
candidate vaccine carrier system capable of eliciting both cell-mediated as well as humoral 
immune responses.  
MARINOSOMES11 
Marinosomes are liposomes based on a natural marine lipid extract containing high 
ratio of polyunsaturated fatty acids (PUFA) like eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), which are not present in normal skin epidermis. They are 
metabolized by skin epidermal enzymes into anti-inflammatory and anti-proliferative 
metabolites that are beneficial in treating inflammatory skin disorders. However, the 
preventing effect of marinosomes was highly dependent on the lipid concentration used and 
the liposome mean diameter. Active and passive loading of drug, as well as complex structural 
rearrangements directly depends on transmembrane pH gradient. All these results allowed 
considering marinosomes as potential candidates for cosmeceutical and oral PUFA 
supplements in view of the prevention and treatment of deficiencies. 
ASPASOMES12 
Vesicles prepared with amphiphiles having antioxidant property may have potential 
applications towards disorders implicated with reactive oxygen species. Ascorbyl palmitate 
(ASP) was explored as bi-layered vesicle forming material. It forms vesicles in combination 
with cholesterol and a negatively charged lipid (dicetyl phosphate). Aspasome rendered much 
better antioxidant activity. 
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ARCHAEOSOME11 
Archaeosome constitute a novel family of liposome made with one or more of the fully 
saturated bipolar tetra ether lipids, which exerts a higher stability in comparison with 
conventional lipids to several conditions such as high temperature, alkaline or acidic pH, and 
presence of phospholipases, bile salts and serum media. They are nano-sized vesicles prepared 
from total polar lipids either extracted from the selected genera and species of the Archaea 
domain or synthetic archaeal lipids. Incorporation of polyethylene glycol and coenzyme Q10 
into archaeosomes has been found to alter the tissue distribution profiles of intravenously 
administered vesicles. Also, intravenous and oral delivery of nanometric-sized archaeosomes 
to an animal model was well tolerated with no apparent toxicity. 
DISCOMES13 
Niosomes are solubilised with Sollulan C24 (polyoxy ethylene cetyl ether class) in 
order to effect vesicle to discome transition. Discomes are relatively large in size (12- 60 
micrometer) and are capable of entrapping high quantities of water- soluble solutes. They were 
found to release the contents following biphasic profile particularly in the case where the drug 
was loaded using pH gradient technique. The prepared system could produce or sustain a 
suitable activity profile upon administration. The discomes were found to be promising and of 
potential for controlled ocular administration of water- soluble drugs. 
BILOSOMES9 
Bilosomes are the novel innovative drug delivery carriers consist of deoxycholic acid 
incorporated into the membrane of niosomes. As conventional vesicles (liposomes and 
niosomes) can cause dissolution and undergo enzymatic degradation in gastro-intestinal tract 
but incorporation of bile salts (commonly used penetration enhancers) in niosomal formulation 
could stabilize the membrane against the detrimental effects of bile acids in GI tract. These 
bile salt stabilized vesicles are known as bilosomes. These are highly biocompatible and have 
been found to improve the therapeutic efficacy of drugs due to their stability in gastro intestinal 
tract. Bilosomes have been found to increase the bio-availability of drugs as they can readily 
absorbed through small intestine to the portal circulation (hepato-circulation). Through this 
circulation they approach to liver and release the drug, so found to be an effective tool in drug 
targeting to liver. 
Introduction… 
 
Department of Pharmaceutics, COP, MMC Page 20 
 
AQUASOMES9 
Aquasomes are three layered structures (i.e. core, coating and drug) that are self- 
assembled through non covalent bonds, ionic bonds and vander-waals forces. They consist of 
tin oxide, nano-crystalline carbon ceramic (diamonds) or brushite (calcium phosphate 
dihydrate) core coated with oligomeric film to which biochemically active molecules are 
adsorbed by copolymerization, diffusion or adsorption with or without modification. The solid 
core provides the structural stability, while the carbohydrate coating protects against 
dehydration and stabilizes the biochemically active molecules. Aquasomes are spherical, 60- 
300nm size particles called “bodies of water”. Due to their size and structural stability, these 
avoid clearance by reticuloendothelial system and degradation by other environmental 
changes. 
HEMOSOMES14 
New artificial oxygen transporting systems engineered by immobilizing haemoglobin 
with polymerisable phospholipids, capable of prolonged activity in the circulation are of 
special interest. Natural hemoglobin was incorporated into liposomes of different composition 
(so- called hemosome). It was shown that the maximal quantity of hemoglobin obtained from 
lysed erythrocytes incorporates into negatively charged liposomes. Stabilized hemosomes bind 
oxygen in the same way as human blood hemolysates.  
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NIOSOMES 
INTRODUCTION 
Vesicles are colloidal particles in which a concentric bilayer made-up of amphiphilic 
molecules surrounds an aqueous compartment. They are a useful vehicle for drug delivery of 
both hydrophobic drugs, which associate with the lipid bilayer and hydrophilic drugs, which 
are encapsulated in the interior aqueous compartment. In general, vesicles made of natural or 
synthetic phospholipids are called liposomes whereas those made of nonionic surfactants (e.g. 
alkyl ethers and alkyl esters) and cholesterol constitutes a nonionic surfactant vesicular system 
called niosomes.15 
Liposomes are colloidal, concentric bi-layered vesicles where aqueous compartment is 
entirely enclosed by a bilayer membrane, mainly composed of natural or synthetic lipids.16 
Disadvantages of Liposomes as Vesicular Drug Delivery System 
 Liposomes are leaky in nature leading to premature drug release. 
 Poor encapsulation efficiency for hydrophilic drug. 
 Liposomes are expensive. 
 Liposomes possess short half-life. 
Requirement of cryogenic atmosphere for the handling of liposomes have prompted the 
use of nonionic surfactants for the preparation of vesicular drug delivery systems. This newly 
introduced vesicular drug delivery system was termed as niosome which consist of unilamellar 
or multilamellar vesicles.  
Niosomes, that is, non-ionic surfactant vesicles, are microscopic lamellar vesicles 
formed when nonionic surfactants (mainly of alkyl or dialkyl polyglycerol ether class) are 
added to cholesterol with subsequent hydration in aqueous media. Addition of cholesterol 
provides rigidity to the bilayer leading to the formation of less permeable niosomes. Addition 
of nonionic surfactants to niosomes increases the size of vesicles and provides charge to the 
vesicles and hence increases the entrapment efficiency of niosomes. Niosomes possess 
structure that is similar to liposomes and hence represent a promising drug delivery module. 
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Niosomes are expected to be better drug carrier system than liposomes upon consideration of 
factors like cost, stability, entrapment efficiency, bioavailability, and so forth.16 
Advantages17 
 They improve the therapeutic performance of the drug by protecting it from biological 
environment and restricting effects to target cells thereby reducing the clearance of the 
drug.  
 They help to accommodate hydrophilic, hydrophobic as well as ampiphilic drug 
moieties, so they can be used for variety of drugs.  
 Niosomes offer a controlled release of drug.  
 They can increase the oral bio-availability of drugs.  
 They are osmotically active and stable.  
 They increase the stability of the entrapped drug.  
 They are flexible and easily modulated.  
 They can enhance the skin penetration of drugs.  
 They can be made to reach the target site by oral, parenteral as well as topical routes.  
 The surfactants are biodegradable, biocompatible, and non-immunogenic.  
 Handling and storage of surfactants are very easy.  
Limitation of niosomal drug delivery system17 
Though niosomal formulation has number of advantages in NDDS system there are a 
few factors that limit its usage.  
 The aqueous suspension of niosomes may have limited shelf life due to fusion, 
aggregation, leaking of entrapped drugs and hydrolysis of encapsulated drug.  
 The preparations of multi-lamellar vesicles such as sonication, extrusion are time 
consuming and required special instruments. 
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Structure of niosomes18 
Fig.2. 
 
Structural components of Niosomes 
1. Surfactants: 
A wide range of surfactants and their combinations in different molar ratios have 
been used to entrap many drugs in niosomes of varying features such as size.  
Non- ionic surfactants are the most common type of surface active agent used in 
preparing vesicles due to the superior benefits they impart with respect to stability, 
compatibility and toxicity compared to their anionic, amphoteric or cationic counterparts. 
They are generally less toxic, less hemolytic and less irritating to cellular surfaces and tend 
to maintain near physiological pH in solution. They are also strong P- glycoprotein 
inhibitors, a property useful for enhancing drug absorption and for targeting to specific 
tissues.15 
The various types of non- ionic surfactants are19 
a. Ether linked surfactants: 
These are polyoxyethylene alkyl ethers which have hydrophilic and hydrophobic 
moieties linked with ether. The general formula of this group is CnEOm, where n can be 
12-18 and m can be 3-7. Surfactants with polyhydroxyl head and ethylene oxide units are 
also reported to be used in niosomes formation. Single alkyl chain surfactant C16 mono 
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alkyl glycerol ether with an average of three glycerol units is one of the examples of this 
class of surfactants used for the preparation of niosomes. Polyoxyethylene cetyl ethers 
(Brij58) and Polyoxyethylene stearyl ethers (Brij72 and 76) are also used in preparation of 
niosomes. 
b. Ester linked surfactants: 
These surfactants have ester linkage between hydrophilic and hydrophobic groups 
and have been studied for its use in the preparation and delivery of sodium stilbogluconate 
to the experimental marine visceral leishmaniasis. 
c. Sorbitan Esters: 
These are most widely used ester linked surfactants especially in food industry. The 
commercial sorbitan esters are mixtures of the partial esters of sorbital and its mono and 
di-anhydrides with oleic acid. These have been used to entrap wide range of drugs viz 
doxorubicin. 
d. Alkyl Amides: 
These are alkyl galactosides and glucosides which have incorporated amino acid 
spacers. The alkyl groups are fully or partially saturated C12 to C22 hydrocarbons and some 
novel amide compounds have fluorocarbon chains. 
e. Fatty Acids and Amino Acid Compounds: 
These are amino acids which are made amphiphilic by addition of hydrophobic 
alkyl side chains and long chain fatty acids which form “Ufasomes” vesicles formed from 
fatty acid bilayers. 
2. Cholesterol:19 
Steroids bring about changes in fluidity and permeability of the bilayer and are thus 
important components. Cholesterol a waxy steroid metabolite is usually added to the non-
ionic surfactants to provide rigidity and orientational order. It does not form the bilayer 
itself and can be incorporated in large molar ratios.  
Cholesterol is an amphiphilic molecule; it orients its -OH group towards aqueous 
phase and aliphatic chain towards surfactant’s hydrocarbon chain. Rigidization is provided 
by alternative positioning of rigid steroidal skeleton with surfactant molecules in the 
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bilayer by restricting the movement of carbons of hydrocarbon. Cholesterol is also known 
to prevent leakage by abolishing gel to liquid phase transition 
3. Charge Inducers:19 
Charge inducers increase the stability of the vesicles by induction of charge on the 
surface of the prepared vesicles. It act by preventing the fusion of vesicles due to repulsive 
forces of the same charge and provide higher values of zeta potential.  
The negative charge inducers are dicetyl phosphate, dihexadecyl phosphate and 
lipoamine acid. 
The positive charge inducers are sterylamine and cetyl pyridinium chloride. 
Types of niosomes20 
The niosomes are classified on the basis of 
 The number of bilayer (e.g. MLV, SUV)  
 Size (e.g. LUV, SUV)  
 The method of preparation (e.g. REV, DRV).  
The various types of niosomes are described below: 
1. Multilamellar vesicles (MLV): 
It consists of a number of bilayer surrounding the aqueous lipid compartment 
separately. The approximate size of these vesicles is 0.5-10 μm diameter. Multilamellar 
vesicles are the most widely used niosomes. It is simple to make and are mechanically 
stable upon storage for long periods. These vesicles are highly suited as drug carrier for 
lipophilic compounds. 
2. Large unilamellar vesicles (LUV): 
Niosomes of this type have a high aqueous/lipid compartment ratio, so that larger 
volumes of bio-active materials can be entrapped with a very economical use of membrane 
lipids. 
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3. Small unilamellar vesicles (SUV): 
These small unilamellar vesicles are mostly prepared from multilamellar vesicles 
by sonication method, French press extrusion, electrostatic stabilization is the inclusion of 
dicetyl phosphate in 5(6)- carboxyfluorescein (CF) loaded Span 60 based niosomes. 
METHODS OF PREPARATION21 
A. Hand shaking method (Thin film hydration technique) 
The mixture of vesicles forming ingredients like surfactant and cholesterol are 
dissolved in a volatile organic solvent (diethyl ether, chloroform or methanol) in a round 
bottom flask. The organic solvent is removed at room temperature (20°C) using rotary 
evaporator leaving a thin layer of solid mixture deposited on the wall of the flask. The dried 
surfactant film can be rehydrated with aqueous phase at 0-60°C with gentle agitation. This 
process forms typical multilamellar niosomes. 
B. Micro fluidization 
Micro fluidization is a recent technique used to prepare unilamellar vesicles of 
defined size distribution. This method is based on submerged jet principle in which two 
fluidized streams interact at ultra high velocities, in precisely defined micro channels 
within the interaction chamber. The impingement of thin liquid sheet along a common front 
is arranged such that the energy supplied to the system remains within the area of niosomes 
formation. The result is a greater uniformity, smaller size and better reproducibility of 
niosomes formed. 
C. Reverse Phase Evaporation Technique (REV) 
Cholesterol and surfactant (1:1) are dissolved in a mixture of ether and chloroform. 
An aqueous phase containing drug is added to this and the resulting two phases are 
sonicated at 4 5°C. The clear gel formed is further sonicated after the addition of a small 
amount of phosphate buffered saline (PBS). The organic phase is removed at40°C under 
low pressure. The resulting viscous niosome suspension is diluted with PBS and heated on 
a water bath at 60°C for 10min to yield niosomes. 
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D. Ether injection method 
This method provides a means of making niosomes by slowly introducing a 
solution of surfactant dissolved in diethyl ether into warm water maintained at 60°C. The 
surfactant mixture in ether is injected through 14-gauge needle into an aqueous solution of 
material. Vaporization of ether leads to formation of single layered vesicles. Depending 
upon the conditions used, the diameter of the vesicle range from 50 to1000 nm. 
E. Trans membrane pH gradient (inside acidic) Drug Uptake Process (remote Loading) 
Surfactant and cholesterol are dissolved in chloroform. The solvent is then 
evaporated under reduced pressure to get a thin film on the wall of the round bottom flask. 
The film is hydrated with citric acid (pH4.0) by vortex mixing. The multilamellar vesicles 
are frozen and thawed 3 times and later sonicated. To this niosomal suspension, aqueous 
solution containing 10 mg/ml of drug is added and vortexed. The pH of the sample is then 
raised to 7.0-7.2 with 1M disodium phosphate. This mixture is later heated at 60°C for 10 
minutes to give niosomes. 
F. The “Bubble” Method 
It is novel technique for the one step preparation of liposomes and niosomes without 
the use of organic solvents. The bubbling unit consists of round-bottomed flask with three 
necks positioned in water bath to control the temperature. Water-cooled reflux and 
thermometer is positioned in the first and second neck and nitrogen supply through the 
third neck. Cholesterol and surfactant are dispersed together in this buffer (pH 7.4) at 70°C, 
the dispersion mixed for 15 seconds with high shear homogenizer and immediately 
afterwards “bubbled” at 70°C using nitrogen gas. 
G. Sonication 
A typical method of production of the vesicles is by sonication of solution as 
described by Cable. In this method an aliquot of drug solution in buffer is added to the 
surfactant/ cholesterol mixture in a 10-ml glass vial. The mixture is probe sonicated at 60°C 
for 3 minutes using a sonicator with a titanium probe to yield niosomes. 
H. Formation of niosomes from proniosomes 
Another method of producing niosomes is to coat a water-soluble carrier such as 
sorbitol with surfactant. The result of the coating process is a dry formulation, in which 
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each water-soluble particle is covered with a thin film of dry surfactant. This preparation 
is termed “Proniosomes”. The niosomes are recognized by the addition of aqueous phase 
at T > Tm and brief agitation.  
T=Temperature. 
Tm = mean phase transition temperature. 
Blazek-Walsh A.I. et al .have reported the formulation of niosomes from 
maltodextrin based proniosomes. This provides rapid reconstitution of niosomes with 
minimal residual carrier. Slurry of maltodextrin and surfactant was dried to form a free 
flowing powder, which could be rehydrated by addition of warm water.21 
Formulation aspects and factors affecting niosome formation 
1. Surfactants15 
The formation of bilayer vesicles instead of micelles is dependent on the 
hydrophilic- lipophilic balance (HLB) of the surfactant, the chemical structure of the 
components and the critical packing parameter (CPP). 
a) Chemical structure of the surfactant15 
The chain length and size of the hydrophilic head group of the nonionic surfactant 
affect the entrapment efficiency of drug. Nonionic surfactants with stearyl (C18) chains 
show higher entrapment efficiency than those with lauryl (C12) chains. The Tween series 
of surfactants bearing a long alkyl chain and a large hydrophilic moiety in combination 
with cholesterol in a 1:1 ratio have the highest entrapment efficiency of water soluble 
drugs. 
b) HLB value and phase transition temperature of surfactant15 
The HLB value of surfactant plays a key role in controlling drug entrapment of the 
vesicle. 
 A surfactant with an HLB value in the range 14- 17 is not suitable to produce niosomes  
 HLB value of 8.6 gives niosomes with the highest entrapment efficiency. 
 Entrapment efficiency decreases as the HLB value decreases from 8.6 to 1.7 
 For HLB> 6, cholesterol must be added to the surfactant in order to form a bilayered 
vesicle and for lower HLB value, cholesterol enhances stability of vesicles. 
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 The entrapment efficiency is affected by the phase transition temperature (Tc) of the 
surfactant. Thus Span 60 with a high Tc exhibits the highest entrapment efficiency. 
 Polyoxyethelene 4- lauryl ether (Brij30) has an HLB value of 9.7, phase transition 
temperature <100°C and cannot be used to formulate some drugs and iodides, mercury 
salts, phenolic substances, salicylates, sulfonamides and tannins as it cause oxidation 
leading to discoloration of product. 
c) Critical packing parameter (CPP)22 and Israelachvili Hypothesis 6  
The key factor that dictates the aggregation of amphiphile molecules into bilayer 
vesicles rather than, for example micelles or liquid crystals, is the molecular shape of the 
amphiphile as this will influence their geometrical packaging within a given solution 
environment. 
Isrealachvili suggested that parameters of self-assemblages are governed by a 
critical packing parameter (CPP). Their self- organization in water is mainly the result of 
the hydrophobic effect, as in the case of soap and detergent, however, it also depends on 
the molecular geometry. The symmetry of lipid self-assembly and liquid crystalline-phase 
formation show strong dependence on the molecular shape of the mesogen/amphipiles. The 
different shapes and volumes constructing different phases are characterized by a 
dimensionless critical packing parameter (CPP)  
CPP = ν/lc Ap = Ahp / Ap 
Where, ν =  Hydrophobic group volume, lc  =  the critical hydrophobic group 
length and Ap = the cross-sectional area of hydrophobic group. 
A CPP below 0.5 (indicating a large contribution from the hydrophilic head group 
area) is reported to give spherical micelles and above 1 (indicating a large contribution 
from the hydrophobic group volume) should produce inverted micelles. A CPP  of 
between 0.5 and 1 indicates that the surfactant is likely to form vesicles. 
The cross sectional geometry of hydrophobic and hydrophilic domain suggests the 
stable geometric configuration. For Ahp > Ap, structures with high curvature (such as 
micelles) are formed. Then the areas are comparable Ahp ≈ Ap  a bilayered configuration 
is the most stable form, while for Ahp < Ap, inverse micelles (with negative surface 
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curvature) are formed. The molecular shape analysis and the concept of shape parameters 
are very useful for qualitative understanding of the topology of lipid vesicles based on 
different lipid composiions. 
2.  Cholesterol 
Inclusion of cholesterol in niosomes increases its hydrodynamic diameter and 
entrapment efficiency. In general, the action of cholesterol is two folds; on one hand, 
cholesterol increases the chain order of liquid-state bilayers and on the other, cholesterol 
decreases the chain order of gel state bilayers. At a high cholesterol concentration, the gel 
state is transformed to a liquid ordered phase.23 
An increase in cholesterol content of the bilayers resulted in a decrease in the 
release rate of encapsulated material and therefore an increase of the rigidity of the bilayers 
obtained. Presence of charge tends to increase the interlamellar distance between 
successive bilayers in multi-lamellar vesicle structure and leads to greater overall entrapped 
volume.23 
The amount of cholesterol to be added depends on the HLB value of the surfactants. 
As the HLB value increases above 10, it is necessary to increase the minimum amount of 
cholesterol to be added in order to compensate for the larger head groups. Higher 
entrapment of Minoxidil occurred in Brij76 niosomes in the presence of a higher content 
of cholesterol whereas no significant increase in entrapment efficiency occurred in Brij52 
(HLB5.3) niosomes. In fact, above a certain level of cholesterol, entrapment efficiency 
decreased possibly due to a decrease in volume diameter (CPP< 0.05).15 
3. Drug23 
Entrapment of drug in niosomes increases vesicle size, probably by interaction of 
solute with surfactant head groups, increasing the charge and mutual repulsion of the 
surfactant bilayers, thereby increasing vesicle size. In polyoxyethylene glycol (PEG) 
coated vesicles, some drug is entrapped in the long PEG chains, thus reducing the tendency 
to increase the size. The hydrophilic lipophilic balance of the drug also affects degree of 
entrapment. 
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4. Resistance to osmotic stress23 
Addition of a hypertonic salt solution to a suspension of niosomes brings about 
reduction in diameter. In hypotonic salt solution, there is initial slow release with slight 
swelling of vesicles probably due to inhibition of eluting fluid from vesicles, followed by 
faster release, which may be due to mechanical loosening of vesicles structure under 
osmotic stress. 
5. Membrane Composition23 
The stable niosomes can be prepared with addition of different additives along with 
surfactants and drugs. Niosomes formed have a number of morphologies and their 
permeability and stability properties can be altered by manipulating membrane 
characteristics by different additives.  
In case of polyhedral niosomes formed from C16G2, the shape of these polyhedral 
niosome remains unaffected by adding low amount of solulan C24 (cholesteryl poly-24- 
oxy ethylene ether), which prevents aggregation due to development of steric hindrance. 
In contrast, spherical niosomes are formed by C16G2: cholesterol: solulan (49:49:2).  
The mean size of niosomes is influenced by membrane composition such as 
Polyhedral niosomes formed by C16G2: solulan C24 in ratio (91:9) having bigger size (8.0 
± 0.03mm) than spherical/tubular niosomes formed by C16G2: cholesterol: solulan C24 in 
ratio (49:49:2) (6.6±0.2mm). Addition of cholesterol molecule to niosomal system 
provides rigidity to the membrane and reduces the leakage of drug from niosome. 
6. Temperature of hydration21 
Hydration temperature influences the shape and size of the niosome. For ideal 
condition it should be above the gel to liquid phase transition temperature of system. 
Temperature change of niosomal system affects assembly of surfactants into vesicles and 
also induces vesicle shape transformation. 
7. pH of hydration medium15 
Entrapment efficiency of niosomes is greatly affected by the pH of the hydration 
medium. High entrapment of flurbiprofen was reported at acidic pH with a maximum 
encapsulation efficiency of 94.6% at pH 5.5. The fraction of flurbiprofen encapsulated 
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increased to about 1.5 times as pH decreased from 8 to 5.5 and decreased significantly at 
pH> 6.8. The lowest entrapment of flurbiprofen occurred at pH 7.4 and 8 with no 
significant difference between them. The increase in encapsulation efficiency of 
flurbiprofen at lower pH is presumably due to its ionizable carboxylic acid group. At lower 
pH, the proportion of unionized flurbiprofen increases and partitions more readily into the 
lipid bilayer than the ionized species. At lower pH, niosome formulations should be 
examined by optical microscopy for the presence of drug precipitates both before and after 
centrifugation and washing. This will help to determine the concentration of drug in the 
hydration medium giving optimum encapsulation in niosomes. 
SEPARATION OF UNENTRAPPED DRUG21 
The removal of unentrapped solute from the vesicles can be accomplished by various 
techniques, which include: - 
1. DIALYSIS 
The aqueous niosomal dispersion is dialyzed in dialysis tubing against phosphate 
buffer or normal saline or glucose solution. 
2. GEL FILTRATION 
The un-entrapped drug is removed by gel filtration of niosomal dispersion through 
a Sephadex-G-50 column and elution with phosphate buffered saline or normal saline. 
3. CENTRIFUGATION 
The niosomal suspension is centrifuged and the supernatant is separated. The pellet 
is washed and then re-suspended to obtain a niosomal suspension free from unentrapped 
drug. 
CHARACTERIZATION OF NIOSOME17, 19 
Size and shape: Shape of niosomal vesicle is assumed to be spherical, and various methods 
can be used for the determination of mean diameter like laser light scattering, electron 
microscopy, molecular sieve chromatography, photon correlation microscopy, optical 
microscopy, freeze fracture microscopy.  
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Bilayer formation: Assembly of non-ionic surfactants to form a bilayer vesicle is 
characterized by an X-cross formation under light polarization microscopy.  
Number of lamellae: This is determined by using nuclear magnetic resonance (NMR) 
spectroscopy, small angle X-ray scattering and electron microscope.  
Membrane rigidity: Membrane rigidity can be measured by means of mobility of 
fluorescence probe as a function of temperature.  
Entrapment efficiency: After preparing niosomal dispersion, unentrapped drug is separated 
by dialysis, centrifugation, or gel filtration as described above and the drug remained entrapped 
in niosomes is determined by complete vesicle disruption using 50% n-propanol or 0.1% Triton 
X-100 and analyzing the resultant solution by appropriate assay method for the drug.  
Entrapment efficiency = (Amount entrapped / total amount) x 100. 
Vesicular surface charge: Niosomes are generally prepared by the inclusion of charged 
molecules in bilayer to prevent the aggregation of vesicles. A reduction in aggregate formation 
was observed when charged molecule like dicetyl phosphate was incorporated in vesicles. The 
charges on vesicles are expressed in terms of zeta potential and calculated using the Henry’s 
equation.  
£ =μEΠ η/Σ 
where, 
£ - Zeta potential 
μE - Electrophoretic mobility 
η - Viscosity of medium 
Σ - Dielectric constant 
Stability study: Stability studies are performed by storing niosome at two different conditions, 
usually 4±1°C and 25±2°C. Formulation size, shape and number of vesicles per cubic mm can 
be measured before and after storing for 30 days. After 15 and 30 days, residual drug can also 
be measured. Light microscope is used for determination of size of vesicles and the numbers 
of vesicles per cubic mm is measured by haemocytometer.  
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Number of niosomes per cubic mm = Total number of niosomes x dilution factor x 400/ Total 
number of small squares counted. 
In- vitro release study17 
Dialysis: A method of in- vitro release rate study was reported with the help of dialysis tubing. 
A dialysis bag was washed and soaked in distilled water. The vesicle suspension was pipetted 
into a bag made up of the tubing and sealed. The bag containing the vesicles was then placed 
in 200 ml buffer solution in a 250 ml beaker with constant shaking at 25°C or 37°C. At various 
time intervals, the buffer was analyzed for the drug content by an appropriate assay method. 
Reverse dialysis: In this technique, niosomes are placed in a number of small dialysis tubes 
containing 1ml of dissolution medium and the niosome are then displaced from the dissolution 
medium. 
Franz diffusion cell: In the Franz diffusion cell, the cellophane membrane is used as the 
dialysis membrane. Niosomes are dialyzed through a cellophane membrane against a suitable 
dissolution medium at room temperature .The samples are withdrawn at suitable time interval 
and analyzed for drug content. 
In- vivo release study:  
Albino rats are used for this study. These rats are subdivided with groups. Niosomal suspension 
used for in- vivo study is injected intravenously (through tail vein) using appropriate disposal 
syringe. 
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APPLICATIONS OF NIOSOMES  
 
Fig. 3. Applications of niosomes. 
The applications of niosomes can be mainly classified into three categories25, 26 
1. For controlled release of drugs 
2. To improve the stability and physical properties of the drugs 
3. For targeting and retention of drug in blood circulation 
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1. For controlled release of drugs 
1.1 To prolong the release rate 
The release rate of drugs like withaferin and gliclazide from the niosomes was 
found slower as compared to other dosage forms. 
1.2 In ophthalmic drug delivery 
Experimental results of the water soluble antibiotic gentamicin sulphate showed a 
substantial change in the release rate. Besides this, the percent entrapment efficiency of 
gentamicin sulphate was altered when administered as niosomes. Also, as compared to 
normal drug solution, niosomes of drug show slow release. 
Niosomal formulation containing timolol maleate (0.25%) prepared by chitosan 
coating exhibited more effect on intra ocular tension with fewer side effects as compared 
to the marketed formulation. 
2. To improve the stability and physical properties of the drugs 
2.1 To increase oral bioavailability 
With the formulation of niosomes, the oral bioavailability of the acyclovir as well 
as griseofulvin was increased as compared to the drug alone. Similarly, the absorptivity of 
poorly absorbed peptide and ergot alkaloid can be increased by the administration in the 
bile duct of rats when administered as micellar solution together with the POE-24- 
cholesteryl ester. 
2.2 For improvement of stability of peptide drugs 
8- arginine, vasopressin, 9- glycinamide-ω 
The in- vitro release of insulin from niosomes formulated by span 40 and span 60 in 
simulated intestinal fluid was lower than the niosomes formulated by span 20 and span 80. 
Niosomes prepared by the span 60 has high resistance against proteolytic enzyme 
and exhibit good stability in storage temperature and in presence of sodium deoxycholate. 
 
2.3 To promote transdermal delivery of drugs 
Many drugs such as lidocaine, estradiol, cyclosporine etc are used for topical and 
transdermal drug delivery system by formulating them as Niosomes 
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The niosomes of natural compound, ammonium glycyrrhizinate were formulated 
for effective anti- inflammatory activity using new non- ionic surfactant, bola surfactant- 
span 80-cholesterol (2:3:1 ratio) 
Experimental study showed that the bola niosomes were able to promote the 
intracellular uptake of ammonium glycerrhizinic acid 
2.4 As a tool for improvement of stability of immunological products 
  Important tool for immunological selectivity, low toxicity and more stability of the 
incorporated active moiety 
2.5 To improve anti- inflammatory activity 
  Niosomal formulation of Diclofenac sodium prepared with 70% cholesterol 
showed greater anti- inflammatory effect as compared to the free drug. 
 Similarly, nimesulide and flurbiprofen showed greater activity than the free drug. 
3. For targeting and retention of drug in blood circulation 
3.1 For increased uptake by A431 cells [a model cell line (epidermoid carcinoma) used in 
biomedical research] 
Chitosan based vesicles incorporating transferrin and glucose as ligands have been 
reported. These vesicles bind CoA (co-A) to their surface. Chitosan containing vesicles are 
then taken up by A431 cells and the uptake was found to be enhanced by transferrin. 
3.2 For liver targeting 
Methotrexate was reported to be selectively taken up by liver cells after 
administration as a niosomal drug delivery system. 
3.3 To improve the efficacy of drugs in cancer therapy 
Niosomes can also be used as a suitable delivery system for the administration of 
drugs like 5-FU 
Niosomes of doxorubicin prepared from C16 monoalkyl glycerol ether with or 
without cholesterol, exhibited an increased level of doxorubicin in tumor cells, serum and 
lungs, but not in liver and spleen 
Niosomal preparation of methotrexate exhibited greater antitumor activity as 
compared to plain drug solution. 
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3.4 In treatment of localized psoriasis 
In the treatment of localized psoriasis, niosomes of methotrexate taking chitosan as 
polymer have shown promising results. 
3.5 In leishmaniasis 
The leishmaniasis parasite mainly infects liver and spleen cells. The commonly 
used drugs, antimonials, may damage the body organ like heart, liver, kidney etc. The 
efficiency of sodium stilbogluconate has been found to be enhanced by incorporation in 
niosomes. The additive effect was observed for two doses given on successive days. 
Moreover, the distribution of antimony in mice showed the higher level of antimony in 
liver after its intravenous administration via niosomal drug formulation. 
3.6 In diagnostic imaging 
It has been studied that niosomes can also act as a carrier radiopharmaceuticals and 
showed site specificity for spleen and liver for their imaging studies using Tc labeled 
DTPA (diethylene triamine pentaacetic acid) containing Niosomes 
Conjugated niosomal formulations of gadobenate with (N- palmitoyl- glucosamine, 
NPG), PEG 4400 and both PEG and NPG can be used to increased tumor targeting of a 
paramagnetic agent 
3.7 Carrier for Haemoglobin 
Niosomes play an important role as a carrier for haemoglobin. The niosomal 
haemoglobin suspension was found to give superimposable curve on free haemoglobin 
curve. 
Usefulness of Niosomes in Cosmetics 
 Niosomes of N- acetyl glucosamine are prepared due to its potential in the delivery of 
hydrophilic and hydrophobic drugs in topical form and improved penetration into the 
skin. Prepared formulations improved the extent of drug localized in the skin, as needed 
in hyperpigmentation disorders.120 
 Elastic niosomes showed increased permeation through the skin which will be 
beneficial for topical anti- ageing application. 
 Suitable for skin moisturizing and tanning products 
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 Niosomes were prepared as possible approach to improve the low skin penetration and 
bioavailability shown by conventional topical vehicle for Minoxidil. 
 Niosomes with added solubilizers enhanced the permeation of ellagic acid (a potent 
antioxidant phytochemical substance which has limited use due to poor 
biopharmaceutical properties, low solubility and low permeability) into the skin with 
increased efficacy of ellagic acid.121 
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REVIEW OF LITERATURE- NIOSOMES  
1. Ismail A. Attia et al.27 formulated acyclovir niosomes in a trial to improve its poor and 
variable oral bioavailability by the conventional thin film hydration method using 
cholesterol, span 60 and dicetyl phosphate in the molar ratio 65:60:5 respectively. The 
formed unilamellar, spherical, shaped vesicles were in the size range 0.4 to 2.2 µm and 
exhibited significantly retarded release compared with free drug; and the in- vitro drug 
release profile was found to follow Higuchi’s equation for free and niosomal drug. The    
in- vivo  study revealed more the 2- fold increase in drug bioavailability in the niosomal 
formulation, which also showed significant increase in the mean residence time (MRT) of 
acyclovir reflecting sustained release characteristics. Thus it was concluded that the 
niosomal formulation could be a promising delivery system for acyclovir with improved 
oral bioavailability and prolonged drug release profiles. 
2. Vyas Jigar et al.28 formulated and evaluated topical niosomal gel of Erythromycin 
antibiotic to enhance skin penetration as well as to improve skin retention of the drug. 
Erythromycin was entrapped into niosomes by thin film hydration technique using           
span 20, span 60, span 80 and cholesterol; and various process parameters were optimized 
by partial factorial design. The optimized formulation was incorporated into carbopol gel 
and extensively characterized for percentage drug entrapment and in- vitro release 
performance. The stability of above formulation was studied at different temperatures. The 
study demonstrated prolongation of drug release, an increase in amount of drug retention 
into skin and improved permeation across the skin after encapsulation of Erythromycin 
into niosomal topical gel. 
3. Y. Prem Kumar et al.29 investigated the effectiveness of using Niosomes in a transdermal 
drug delivery system for Econazole, since topically applied Niosomes can increase the 
longer action on the skin (stratum corneum and epidermis), while reducing the systemic 
absorption of the drug. Econazole niosomes were prepared by thin film hydration technique 
by varying the cholesterol and span 80 ratios as 1:1, 1:2, 1:3 and 1:4. Each formulation was 
evaluated for drug release. The release showed required amount of drug release per day as 
well as extended for the required day is the optimized formulation. Hence, 1:4 ratio was 
concluded as best and was found to follow zero order release kinetics. 
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4. R. Parthibarajan et al.30 designed Voriconazole niosomes by hand shaking and ether 
injection method using various ratios of span 80 and cholesterol and characterized the best 
formulation in terms of vesicle size distribution, entrapment efficiency and in- vitro release 
studies. Interaction of drug and the different ingredients in the niosomes were studied by 
FTIR spectra and found to be compatible. The entrapment efficiency and in- vitro drug 
release profile of voriconazole niosomes were determined by dialysis method. The 
evaluation results showed niosomes prepared by hand shaking method to be superior with 
entrapment efficiency of more than 84.53% and an entended release of 70.06% of drug up 
to 24 hours. It was concluded that in- vitro release of Voriconazole from niosomes was 
very slow when compared to the release from pure Voriconazole solution. 
5. Abdallah Marwa et al.31 studied the formulation of niosomes as carriers for delivery of 
diclofenac sodium using a series of sorbitan monoesters (Span 20, 40,60 and 80) and 
sorbitan trioleate (Span 85) and co- surfactants of polyoxyethylene fatty acid esters (Tween 
20, 40, 60 and 80), with or without cholesterol and charged lipids like stearylamine or 
dicetylphosphate. The prepared niosomes were evaluated for entrapment efficiency and    
in- vitro release rate. Niosomes formed of span 60 gave the highest entrapment efficiency 
and showed the slowest release rate than those prepared from Span 20, 80 and 85. 
Niosomes prepared by ether- injection and reverse- phase evaporation method resulted in 
a marked increase in the entrapment efficiency compared to those prepared by hand- 
shaking method. It was also found that increasing the total lipid concentration resulted in 
an increase in the percentage entrapment efficiency, which also resulted while using co- 
surfactants like different types of Tween with Cholesterol in a molar ratio of 25:25:50. 
Hence, the incorporation of co- surfactants into niosomes resulted in a greater decrease in 
the release rate of diclofenac sodium from niosomal vesicles. 
6. Narayana Charyulu R et al.32 studied the influence of bio-enhancers on the release pattern 
of niosomes containing methotrexate by preparing sustained release formulations of 
niosomes of methotrexate alone and along with bio-enhancers by thin film hydration 
technique using span 60 as surfactant, cholesterol as membrane stabilizing agent, curcumin 
and piperine as bio-enhancers and dicetyl phosphate as charge inducing agent. All the 
formulations of niosomes were characterized on the basis of physical appearance and 
entrapment efficiency. The in- vitro release studies of optimized formulation of niosomes 
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were performed and compared with pure drug release. The entrapment efficiency of MTX 
with bioenhancers curcumin and piperine was found to be 40.30% and 69.1% respectively. 
In- vitrodrug release of optimized formulation of MTX alone and with bioenhancers (F3) 
was found to be 98.89% and 60.97% at the end of 12 hours respectively. Results concluded 
that niosomes of MTX containing bioenhancers followed sustain release pattern. 
7. K. Sabarikumar et al.33 studied the bioavailability enhancement of Aceclofenac  niosomes 
containing surfactants and cholesterol. The evaluation study included the effect of varying 
composition of non- ionic surfactant and cholesterol on the properties such as 
encapsulation efficiency, particle size, scanning electron microscopy and in- vitro drug 
release of Aceclofenac. The drug release was found to be modified and extended over a 
period of 72 hours in all formulations. The results of in- vitro drug release studies showed 
that formulation ANF-3 (Span 60 1:2:1) has better modified and extended release of drug 
(92.19%) for 72 hours. hence,ANF-3  emerged as the most satisfactory formulation in so 
far as its properties were concerned. 
8. Shete AS et al.34 developed and characterized PEGylated lipid coated niosomes of 5- fluoro 
uracil for parenteral drug delivery. The stealth niosomes were prepared by ether injection 
method using span 60 and the niosomal dispersion as bath sonicated for different period of 
time to reduce particle size at or above the phase transition temperature of surfactant. The 
performed niosomes were incubated with PEGylated lipid (5mol %) for 30 minutes. The 
un-entrapped drug was separated by centrifugation. It was observed that with increase in 
total molar concentration of surfactant and cholesterol, % entrapment efficiency increased. 
It was found that increase in sonication time reduces the particle size of the niosomes. 
PEGylated lipid coated niosomes were found to be larger than the conventional ones. The 
PEGylated lipid coated niosomes showed controlled in- vitro release of 5-FU for 6 hours. 
Stability study indicates that the PEGylated niosomes showed more drug retention stability 
than conventional niosomes. 
9. Prabagar Balakrishnan et al.35 performed formulation and in – vitro assessment of 
Minoxidil for enhanced skin delivery. Niosomes formed from Brij or Span with cholesterol 
molar ratios of 0,1,1.5 were prepared with varying drug amount 20-50 mg using thin film 
hydration method. The prepared systems were characterized for entrapment efficiency, 
particle size, zeta potential and stability. Skin permeation studies were performed using 
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static vertical diffusion Franz cells and hairless mouse skin treated with either niosomes, 
control Minoxidil solution or a leading topical Minoxidil commercial formulation 
(Minoxyl). Higher entrapment efficiency was obtained with the niosomes prepared from 
Span 60 and cholesterol at 1:1 molar ratio using 25 mg drug. Niosomal formulations have 
shown a fairly high retention of Minoxidil inside the vesicles (80%) at refrigerated 
temperature up to a period of 3 months. It was observed that both dialyzed and non- 
dialyzed niosomal formulations enhanced the percentage of dose accumulated in the skin 
compared to commercial and control formulations except dialyzed span 60 niosomes. The 
greatest skin accumulation was always obtained with non- dialyzed vesicular formulations. 
The results suggested that these niosomal formulations could constitute a promising 
approach for the topical delivery of Minoxidil in hair loss treatment. 
10. Sanket Dharashivkar et al.36 developed novel sustained release once a day niosomal 
formulation of Silver Sulphadiazine (SSD) in order to improve the patient compliance. 
Niosomes were prepared using different nonionic surfactants and cholesterol in the molar 
ratio of 1:1 by the ethanol injection method. Effect of different formulation variables like 
curing time, surfactant structure, HLB and molecular weight of a surfactant, on entrapment 
efficiency of SSD in niosomes were evaluated. Results indicated that the niosomes 
manufactured with span 60 gives highest entrapment and all niosomal formulations 
exhibited considerably retarded in- vitro release by a higuchi controlled mechanism. For 
span 60 niosomes the release was 98.14% over 28 hours. In- vitro antimicrobial study using 
Pseudomonas aeruginosa revealed that the niosomal formulation of SSD shows a better 
zone of inhibition (14mm) in comparison to conventional dosage form (12mm) even when 
used in half the concentration of conventional dosage form. This study showed that the 
niosomal formulation of SSD can be used as the promising sustained release approach for 
the topical delivery of SSD in burn treatment. 
11. Priya Hanu and Singh Harmanpreet37 formulated niosomes of Punicalagin, a 
hydrolysable tannin extracted from peels of Punica granatum in order to protect it from 
hydrolysis. The niosomes were formulated using varying amounts of span 60 and keeping 
the amount of cholesterol constant. The formulations were evaluated on the basis of 
morphology, entrapment efficiency, zeta potential and stability of the niosomes. As 
compared to other formulations F7 containing surfactant and cholesterol in ration 7:1 had 
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maximum entrapment efficiency of 65.93% and hence was selected as optimized 
formulated. 
12. Varaporn Buraphacheep Junyaprasert et al.38 investigated the influence of chemical 
penetration enhancers on the physicochemical properties of ellagic acid loaded niosomes. 
The ellagic acid niosomes were prepared by reverse phase evaporation method using Span 
60, Tween 60 and cholesterol and Solulan C24 as a steric stabilizer. PEG was used as a 
solubilizer while DMSO or N-methyl 2- pyrrolidone (NMP) was used as a skin penetration 
enhancer. The formed spherical multilamellar vesicles were stable after 4 months storage 
at 4ºC. The DMSO niosomes showed the highest ellagic acid amount in epidermis; whereas 
the NMP niosomes had the highest ellagic acid amount in the acceptor medium. The results 
concluded that the DMSO niosomes were suitable for epidermis delivery of ellagic acid 
while the NMP niosomes can be used for dermis delivery of ellagic acid. 
13. Anchal Sankhyan and Pravin K Pawar39 prepared Metformin loaded non- ionic 
surfactant vesicles using thin film hydration technique and investigated for morphology, 
entrapment, in- vitro release, TEM and physical stability. Optimized formulation was 
further studied for the effect of surfactant concentration, DCP, surfactant: cholesterol ratio 
and volume of hydration. It was resulted that 100 molar concentration of cholesterol and 
surfactant, presence of DCP, equimolar ratio of span 60: cholesterol and 15ml of volume 
of hydration were found to be optimum for niosome preparation. The release studies data 
was subjected to release kinetics models. The present work concluded Metformin loaded 
niosomes to be effective in sustaining the drug release leading to decreased side effects and 
increased patient compliance. 
14. Shweta Patidar and Shelesh Jain40 investigated non ionic surfactant based vesicles 
containing Flupirtine Maleate as an Ocular drug delivery system to improve the low corneal 
permeability for effective management of trigeminal neuralgia. Niosomes formed 
immediately upon hydrating proniosomal gel which were developed with span 20, span 60, 
span 80, tween 20 and tween 80 with cholesterol, were characterized for morphology, 
entrapment efficiency, in- vitro drug release, drug release kinetics, stability, ocular 
irritation test and in- vivo eye wiping test for trigeminal neuralgia. The entrapment 
efficiency determined by centrifugation of freeze thawed vesicles followed the order span 
80> span 60> span 20> tween 20> tween 80.the in- vitro release studies showed that there 
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was a prolonged release of drug which followed Higuchi model. Niosomes formed from 
span 80 and cholesterol s promising approach to prolong anti nociception activity and 
improve permeation rate as compared to pure drug. 
15. Tejaswi lella, M. Kishore Babu41 formulated Olanzapine niosomal suspensions by thin 
film hydration technique with a view to targeting the drug to the brain and produce a 
sustained release to increase the retention time of the drug in the brain. The higher values 
of entrapment efficiency were obtained with span 60, followed by span 20 and span 80. 
Drug entrapment efficiency was found to increase with increase in molar concentration of 
cholesterol. The highest percentages of drug release were obtained with niosomes prepared 
with span 60. The in- vitro diffusion studies followed first order kinetics and ascertained 
peppa’s mechanism, governed by non- Fickian diffusion. High negative surface charge on 
niosomes by zeta analysis indicated high stability. The results concluded that the niosomal 
formulation F5 could be a better choice in the view of entrapment efficiency and drug 
release rate for the effective management of psychotic disorders. 
16. S. Dugal and A. Chaudhary42 investigated the potential of niosomes to aid in the slow 
sustained release of the topical antiseptic povidone- iodine (PVP- I) in order to overcome 
the major drawback of contact burns and other adverse reactions attributed to its sudden 
concentrated release from absorbent skin bandages. The niosomes were developed by the 
thin film hydration technique with stoichiometric proportion of antiseptic: cholesterol: 
sorbitan monooleate of 1:1:2; and was characterized for their particle size, zeta potential, 
drug entrapment efficiency, in- vitro agar cup tests and in- vitro drug release profile. The 
MIC of PVP- I for Candida was found to be 0.45% w/v of available iodine. The average 
size of loaded vesicles was 338.4 nm, with a drug entrapment efficiency of 80%. The 
encapsulated PVP- I showed good permeability, retention of the fungicidal activity and 
slow sustained effect lasted for almost 35 hours. The result demonstrated that niosomes 
can act as micro reservoirs to prolong the release of PVP- I and thus could help prevent 
contact burns associated with the immediate release of the antiseptic when used for topical 
application. 
17. Vijay S. Jatav et al.43 prepared rifampicin loaded niosomes by hand shaking method using 
surfactant and cholesterol in 50:60 percent mol fraction ratio. The percent of drug 
entrapped was noted to decrease progressively in the order span 85> Span 80> Span 60> 
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Span 40> Span 20; and the cumulative percent rifampicin released was maximum for Span 
20 and minimum for Span 85 based niosomes. Thus it was concluded that handshaking 
method is a simple and efficient technique for designing functional niosomes for 
hydrophobic and amphiphilic drugs. 
18. Omar S. Salih et al.44 formulated a niosomal dosage form of rosuvastatin calcium with a 
view to improve its dissolution and permeability. The formulation was done by film 
hydration method using span 20, span 60 and span 80, cholesterol and lecithin in different 
ratios and evaluated in terms of assay by HPLC, particle size, morphology, in- vitro  drug 
release and ex- vivo permeation study, SEM, TEM and FTIR. All formulas gave obvious 
morphology in the presence of cholesterol as a stabilizing agent and formula with span 60 
had more entrapment efficiency than others with slower release after 7 hours in- vitro 
dissolution media. It was concluded that niosomes were promising dosage form to enhance 
dissolution and permeability of slightly soluble drugs prepared by film hydration method. 
19. Samyuktha Rani B and Vedha Hari B N45 prepared Orlistat niosomes from proniosome 
by reverse phase evaporation technique (slurry method) in rotary flash evaporator to 
improve its poor and variable oral bioavailability. The lipid mixture consisted of 
cholesterol, span 60 and beta cyclodextrin carrier in molar ratios 0.1:0.9:1 to 0.9:0.1:1 
respectively. The niosomes were evaluated for particle size, entrapment efficiency, in- vitro 
drug release, release kinetics, FTIR, SEM, stability studies, conductivity and sedimentation 
rate, pH, density and viscosity. The niosomes had a mean size of 100nm with a smooth 
surface. Formulation OT9 was found to be the best with %EE of 44.09% and in- vitro 
release of 94.59% at the end of 12 hours. Release followed Hixson kinetics for diffusion 
and the niosomes had appropriate stability for 90 days at room temperature. Thus the 
niosomal formulations could be a promising delivery system for Orlistat with improved 
oral bioavailability, stability and for sustained drug release. 
20. Ye Jin et al.46 developed niosomal system to deliver Gingko biloba extract (GbE) with 
improved oral bioavailability and to replace the conventional GbE tablet. The GbE 
niosomes were prepared by film dispersion- homogenization method which was further 
freeze dried or spray dried to improve the stability of the niosomes. The characterization 
was done on the basis of morphology, particle size, zeta potential, entrapment efficiency, 
angle of repose, DSC, in- vitro release and in- vivo distribution study. The spray drying 
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method yielded niosomes with %EE of 77.5% with 50.1% for freeze dried niosomes. The 
niosomes showed a prolonged release up to 48 hours and the GbE niosomes were also 
detected in the rat brain tissue. Hence it was concluded that niosomes are a promising oral 
system for delivery of GbE to the brain. 
REVIEW OF LITERATURE- KETOCONAZOLE 
1. R. Shireesh kiran89 et al. had investigated the ketoconazole nail lacquer as ungual drug 
delivery system for the treatment of onychomycosis. Topical therapy of nail diseases is 
limited by the poor permeability of nail plate. they had used few ungual enhancers like 
thioglycollic acid (TA) and urea hydrogen peroxide and investigated their effect on the nail 
permeation of ketoconazole drug. In-vitro drug permeation studies were carried out across 
human nail plates using Franz diffusion cells. They stated that significantly higher 
permeation was achieved in the presence of thioglycollic acid as enhancer. 
 
2. Junxiu Che et al.  had investigated to develop a ternary skin targeting system for 
ketoconazole using a combined strategy of micro emulsion and cyclodextrin ( beta- 
hydroxyl cyclodextrin) i.e KET-CD-ME. The KET-CD-ME was formulated using Labrafil 
M 1944 CS as oil phase, Solutol HS 15 as surfactant, Transcutol P as cosurfactant, and HP-
β-CD solution as aqueous phase.in-vitro sensitivity against candida parapsilosis test 
indicated that KET-CD-ME enhanced KET anti- fungal activity mainly owing to the 
solubilisation of HP-β-CD on KET in the ternary system. 
 
 
3. M Najmuddin et al. 91formulated the solid dispersion incorporated gel of ketoconazole.  
The solubility of ketoconazole was increased by complexation with β cyclodextrin which 
was prepared by solvent evaporation technique and then incorporated into gels. 
Ketoconazole gel formulations were made with different polymers like carbopol 940, 
HPMC, Methyl cellulose and sodium carboxy methyl cellulose containing various 
permeation enhancers like sodium lauryl sulphate, dimethyl sulfoxide in different 
proportions. The formulated gels were evaluated for various physiochemical parameters  
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and showed good spreadability, extrudability. The carbopol 940 with 15% of dimethyl 
sulfoxide showed better drug release at the end of 6 hrs. 
4. P.M. Satturwar et al.112 had prepared Ketoconazole niosomes by ether injection technique 
using surfactant (Tween 40 or 80), cholesterol and drug in five different ratios by weight. 
They were characterized for size, shape, entrapment efficiency and in-vitro drug release 
(by exhaustive dialysis). The formulations were also tested for in-vitro (cup plate method) 
and in-vivo  anti – fungal activity (in rabbits) and compared with free ketoconazole. The 
results indicate that niosomes have potential to reduce the therapeutic dose of ketoconazole 
by improving its performance. 
5. Rakesh P.Patel et al.93 had formulated ketoconazole liposomes by thin film hydration 
technique using soya lechithin, cholesterol and drug in different ratios. The prepared 
liposomes were characterized for size, shape, entrapment efficiency, in-vitro drug release 
(by Franz diffusion cell) and physical stability. The studies demonstrated successful 
preparation of ketoconazole liposomes and effect of soya lecithin: cholesterol weight ratio 
on entrapment efficiency and on drug release. 
6. Dattatreya B Udgirkar et al.95  had formulated buccoadhesive tablets of ketoconazole by 
using HPMC K4M and Carbopol 934 P as bio adhesive polymers and Ethylcellulose (EC) 
as baking material. The solubility of  ketoconazole was increased by inclusion complex 
with β-cyclodextrin and then delivery via buccal mucosa. The bucco adhesive tablets for 
the delivery of ketoconazole were prepared by 32  factorial design; Direct compression of 
HPMC K4M and Carbopol 934P. the results of  various studies revealed that there was 
increase in drug release rate from the tablets in solution as well as permeated through sheep 
buccal mucosa and showed better potential for buccal administration. 
7. Rahul R. Patel et al.96 had developed micro emulsion based gel (MBG)  formulation of 
ketoconazole for enhancing its solubility and permeability. MBG was prepared with 
Capmul MCM NF as oil, Acrysol K150 as surfactant, propylene glycol as co-surfactant, 
carbopol as gelling agent. They had optimized the system by ternary phase diagram. They 
had analysed the formulations for Drug content, % transmittance, visual assessment, 
particle size and zeta potential analysis. In-vitro release of the formulations showed better 
release than the marketed formulation. Hence, it has significant increase in solubility of 
ketoconazole. 
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8. M. ABD Elgadir et al.98 had investigated the relationship between water number value of 
selected ointments and release of ketoconazole as a model drug. They had used the 
ointment bases like soft paraffin, wool fat, cetostearyl alcohol, and soft paraffin. They had 
stated in their results that the addition of a fatty alcohol as cetostearyl alcohol to soft 
paraffin has increased the water number from 11.5 to 57.5 ml. 
9. Mirela Adriana Mitu et al.97 had investigated the influence of the receptor media on the 
in-vitro diffusion kinetics of Ketoconazole topical pharmaceutical formulations using a 
vertical diffusion cell system and two types of receptor media which differs by the 
solubilizing capacity for the active pharmaceutical ingredient. The experimental results 
indicated the impact of both composition of the receptor media and nature of the 
pharmaceutical dosage form on the dissolution profiles. 
10. M. Skiba et al.113 had investigated the stability assessment of ketoconazole in aqueous 
formulations. The stability of ketoconazole in aqueous media was assessed as a function of 
pH, antioxidant and ketoconazole concentration.it was found that ketoconazole was least 
stable at pH 1. The viscosity of the formulation was found to be more stable at high pH 
because carbopol is stable at basic pH and protected ketoconazole. It appears that the 
amount of ketoconazole in the formulation has a low influence on the degradation stability 
of ketoconazole. 
11. Nagoba S.N. et al.99 formulated ketoconazole as a tablet lozenge to provide slow release 
medicament for the treatment of oral thrush in pediatric patients. The lozenges were 
prepared by heating and congealing method in a candy base. the prepared formulations 
were subjected to various physiochemical parameters like hardness, content uniformity, 
friability, weight variation, stability studies etc. In all the tests performed, the lozenges 
show better results and could be an attractive alternative formulation in the treatment of 
oral thrush in pediatric patients. 
12. Rolando E. Saenz et al. 86 had compared the efficacy of anti-fungal drug ketoconazole 
(600 mg/day for 28 days) with a recommended regimen of intramuscular pentostam  in a 
randomized study of the treatment of Panamanian cutaneous leishmaiasis due to leishmania 
braziliensis panamensis. Ketoconazole clinically cured 16 of 21 patients. Both keoconazole 
and pentostam were more effective than placebo against L. braziliensis panamensis 
cutaneous leishmaniasis. 
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LITERATURE REVIEW ON NIOSOMAL GEL 
1. Loveleen Preet Kaur et al.115 had reviewed the topical gel formulations in the novel drug 
delivery system. Gel formulation provides better application property and stability in 
comparison to cream and ointment. Topical application of drugs offers potential 
advantages of delivering the drug directly to the site of action and acting for an extended 
period of time. They had presented various classification of gels, method preparation, 
various evaluation parameters etc. Gels are evaluated by following parameters such as pH, 
homogeneity, grittiness drug content, viscosity, spreadability, extrudability, skin irritation 
studies, in-vitro release, in Stability 
2. P.S. Salve117 had developed a topical drug delivery system using niosomal gel. Niosomes 
of terbinafine hydrochloride was prepared by thin film hydration method in size range of 
0.24 to 9.4 µm. zeta potential of niosomes containing span 60 (1:1) were more stable than 
other formulations. Niosomes were incorporated in 1.5 % w/v carbopol gel at pH 6.8 to 
7.0. In in-vitro anti-fungal against candida albicans, vesicular systems are more effective 
than conventional gel. In ex-vivo percutaneous permeation studies, niosomal formulations 
have shown superior skin penetration and drug deposition. The formulation containing 
tween 80 has shown higher drug deposition in rat skin as compared to other formulations. 
3. V.Sathyavathi et al.118 developed niosomal in-situ gel for glaucoma treatment. The 
problem of poor bioavaiability of ocular drugs due to tear production, non-productive 
absorption, transient residence time can be minimized by the use of niosomal vesicular 
system. niosomes were formulated by using different ratios of span series and cholesterol. 
In-situ gelling of niosomal drops was formulated by using HPMC K 15 M and carbopol 
940 to maintain the drug localization for extended period of time. All the gel formulations 
exhibit pseudo plastic rheological behavior and slow drug release pattern. Anti-glaucoma 
activity of the prepared gel formulations showed more significant and sustained effect in 
reducing intra ocular than marketed and niosomal drops. 
4. T.Coviello et al.119 had prepared gels with xanthan and Locust bean gum and loaded with 
nonionic surfactant vesicles., the vesicles composed by Tween 80 and cholesterol or by 
tween 85 and span 20 were loaded with monosodium glycyrrhizinate for release 
experiments. Size and zeta potential of the vesicles were evaluated and the new systems 
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were characterized by rheological and dynamo-mechanical measurements. For an 
appropriate comparison, a carbopol gel and commercial gel were also evaluated. In-vitro  
experiments showed that the polysaccharide network protects the integrity of the vesicles 
and leads their slow release without disruption of the aggregated structures. Further more, 
being the vesicles composed of molecules possessing enhancing properties, the permeation 
of the loaded dugs topically delivered can be improved. thus, the new system combine the 
advantages of matrices for a modified release (polymeric component) and those of an easier 
permeability 
5. Jigar Vyas et al.116 had entrapped Benzoyl peroxide into niosomes by thin film hydration 
technique and various process parameters were optimized by partial factorial design. The 
optimized niosomal gel formulation was incorporated into HPMC K15 and extensively 
characterized for percentage drug entrapment and in-vitro release performance. Their study 
had demonstrated prolongation of drug release, increased drug retention into skin, and 
improved permeation across the skin after encapsulation of benzoyl peroxide into niosomal 
gel. 
6. P.K.Lakshmi et al.114 had prepared methotrexate niosomes by lipid layer hydration 
method. The characterized niosomes were incorporated into chitosan gels. The gels were 
tested for irritation and skin sensitivity by human repeated insult patch test. The 
formulations were assessed for efficacy by double blind placebo controlled study in 10 
psoriasis patients for each formulation. The results suggest that niosomal methotrexate gel 
is more efficacious than placebo and marketed methotrexate gel. 
REVIEW OF LITERATURE ON LEISHMANIASIS 
1. Ramzi A.Mothana et al.80 evaluated the anti-plasmodial, antileishmanial and 
antitrypanosomal activity of twenty-five medicinal plants distributed in Saudi Arabia and 
Yemen. The plants were extracted with methanol and screened in-vitro against erythroytic 
schizonts of plasmodium falciparum, intracellular amastigotes of Leishmania infantum and 
trypanosomeruzi and free trypomastigotes of T.brucei. Interesting activity against 
L.infantum was obtained with Verbascum bottae and Solanum glabratum(IC50 8.1 µg/ml,SI 
3.4). these results partly support the traditional use of some of the selected medicinal plants 
and warrant further investigations into the putative active constituents. 
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2. S.Lala et al.81 investigated the in-vitro anti-leishmanial activity of 14-deoxy-11-
oxoandrographolide a derivative of andrographolide, isolated from the Indian medicinal 
plant Andrographis paniculata in different vesicular delivery modes on hamster model of 
Leishmaniasis. The drug in various delivery modes, particularly in liposomal and niosomal 
forms showed apparently no immediate toxicity. Hence, these forms of 14-deoxy-11-
oxoandrographolide might have clinical application to combat visceral Leishmaniasis. 
3. Payam Khazaeli et al.82 had prepared and evaluated the effect of itraconazole niosome on 
the in-vitro susceptibility of Leishmania tropica  as compared to itraconazole alone or tartar 
emetic. The overall growth rate of promastigotes treated with various concentrations of 
itraconazole niosomes was significantly lower than itraconazole alone. Their findings 
indicated that niosomes could be developed as novel drug delivery for itraconazole in the 
in-vitro model. 
4. Heibatullah Kalantari et al.87 had investigated the effect of topical nanoliposomes of anti-
leishmanial drug Paromomycin on rats liver and kidney. They had evaluated the probable 
nephrotoxicity and hepatotoxicity of topically administered PMS liposomes. their report 
states that the application of nanoliposomal paromomycin sulfate formulations for topical 
treatment of the cutaneous leishmaniasis does not create serious side effects in the short 
term use. 
5. Umakant Sharma et al.85 had investigated the antiparasitic activity of plumericin & 
isoplumericin isolated from Plumeria bicolor against Leishmania donovani. The plumeria 
bicolor extract showed activity with the IC50 of 21±2.2 and 14±1.6 µg/ml against 
promastigote and amastigote forms, respectively. Hence, their results indicated plumericin 
has a promising anti-leishmanial activity. 
6. Luciana S.Ferreira et al.84 had investigated the in-vitro skin permeation and retention of 
paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. 
Liposomal formulation usually provide sustained and enhanced drug levels of 
paromomycin. Controlled topical delivery, across stripped skin was observed for PA 
entrapped in liposomes. 
7. Rolando E. Saenz et al86 had compared the efficacy of anti-fungal drug ketoconazole (600 
mg/day for 28 days) with a recommended regimen of intramuscular pentostam  in a 
randomized study of the treatment of Panamanian cutaneous leishmaiasis due to leishmania 
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braziliensis panamensis. Ketoconazole clinically cured 16 of 21 patients. Both keoconazole 
and pentostam were more effective than placebo against L. braziliensis panamensis 
cutaneous leishmaniasis. 
8. Elena pinelli et al.111 had used the canine macrophage cell line (030-D) that can 
readily be infected with Leishmania infantum. Their objective is to further characterize the 
effector mechanisms involved in killing of Leishmania parasites in dogs. They had 
observed that activation of 030-D cells resulted in enhanced nitric oxide (NO) 
productionby these cells.hence, they proposed the infection of the 030-D cell line as a good 
in-vitro model to further investigate parasite-host cell interactions in dogs. 
3. AIM AND PLAN OF WORK 
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AIM OF WORK 
The aim of the present study is 
 To formulate Ketoconazole niosomal gel drug delivery system using various non -ionic 
surfactants and cholesterol to enhance its therapeutic efficacy by controlled release. 
 To provide an efficient dosage form by targeting it to the macrophages for the treatment 
of Cutaneous Leishmaniasis. 
PLAN OF WORK 
The present work was designed and planned as follows: 
 Drug excipients compatibility studies- FT- IR study 
 Determination of λmax of Ketoconazole in phosphate buffered saline pH 7.4 
 Calibration curve of the drug in phosphate buffered saline pH 7.4 
 Preformulation studies and optimization of process related variables using niosomes 
prepared in different molar ratios of non- ionic surfactant (Span 40) and constant molar 
ratio of cholesterol (25 µmol) by thin film hydration technique. 
 Effect of hydration time 
 Effect of capacity and rotational speed of evaporator flask 
 Effect of Sonication time 
 Effect of osmotic shock 
 Formulation of Ketoconazole niosomes using optimized process parameters using 
various molar ratios of different non- ionic surfactants keeping cholesterol constant at 
25 µmol. 
 Evaluation of Ketoconazole niosomes 
 Drug content 
 Entrapment efficiency by centrifugation method 
 In- vitro drug release study of niosomal formulations and Ketoconazole drug 
solution in phosphate buffered saline pH 7.4 using dialysis membrane 
 In- vitro release kinetics 
 Selection of best ratio and preparation of Ketoconazole niosomal gel using various non- ionic 
surfactants (Span 20, Span 40 and Span 60). 
 Determination of particle size distribution using Malvern zeta analyzer. 
 Morphological studies using Optical microscopy and Scanning electron microscopy(SEM). 
 Aim and plan of work… 
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 Formulation of Ketoconazole Niosomal gel using the optimized ratio of surfactants. 
 Evaluation of Ketoconazole Niosomal gel. 
 Physical appearance 
 pH of the gel 
 Rheology – Brookefield Viscometer 
 Drug content estimation 
 Entrapment Efficiency 
 In-vitro Drug Diffusion study. 
 Stability study of the optimized niosomal gel formulations. 
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RATIONALE OF THE STUDY6, 76, 81, 82, 83 
Leishmaniasis is one of the world’s most neglected diseases largely affecting the 
poorest of the poor, mainly in developing countries. Over 350 million people are considered at 
risk of contracting leishmaniasis and approximately 2 million new cases occur yearly.83   
Although Cutaneous Leishmaniasis (CL) is a self- healing disease, it can result in disfiguring 
scar and long-lasting stigmas, which may destroy underlying structures like nose, ear or the 
exposed sites of skin which causes the psychological suffering of patients.82 
Although Pentavalent antimonials (SbV) are still considered the first line of treatment 
for all forms of Leishmaniasis, there are some reports of drug resistance and unresponsiveness 
to the treatment with these drugs. While, the second line of drugs such as pentamidine and 
amphotericin B have low efficacy with side effects. Therefore it is desirable that new drugs as 
well as new delivery systems developed to enhance the efficacy and to reduce the toxicity.81 
Anti-fungal agents including azole derivatives (fluconazole, econazole, miconazole, 
ketoconazole and itraconazole) have had clinically acceptable leishmanicidal activities.  
RATIONALE FOR SELECTION OF DRUG 76, 122 
Ketoconazole is a synthetic imidazole anti-fungal drug used primarily to treat fungal 
infections.122 It has shown activity against Leishmaniasis by interfering with the sterol 
biosynthesis present in the leishmanial membranes. Like fungi, Leishmania synthesize 24-
substituted sterols, such as ergosterol (mammals have cholesterol). Ketoconazole inhibit a key 
enzyme of this pathway 14 α demethylase. Ketoconazole has given equivocal results in trials 
against both CL and VL.76 
RATIONALE FOR SELECTION OF DOSAGE FORM 6, 24 
The purpose of this research work was to formulate and optimize the niosomal gel drug  
delivery system containing Ketoconazole to enhance its therapeutic efficacy by controlled 
release and by targeting it to the reticulo endothelial system (RES). Vesicular drug delivery 
system plays a major role in modeling biological membranes and in the transport and targeting 
of active agents. 
Rationale of study… 
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Passive capture of colloidal carriers by macrophage offers therapeutic opportunities for 
the delivery of anti-infectives for disease conditions that involve macrophage cells of the 
reticuloendothelial system (RES) e.g., leishmaniasis.6 
Niosomes have been reported to offer the following advantages 
 Targeted drug delivery 
 Protection of drug 
 Increased bioavailability 
 Sustained release 
 Enhanced cellular uptake6 
The above aspects led to the formulation of Ketoconazole niosomal gel drug delivery 
system which establishes and maintains the drug concentration at the target site for a prolonged 
period of time.  
5.DISEASE PROFILE… 
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NEGLECTED TROPICAL DISEASES109 
Neglected tropical diseases (NTDs) are a diverse group of 
communicable diseases that prevail in tropical and subtropical 
conditions in 149 countries and affect more than one billion 
people, costing developing economies billions of dollars every 
year. They mainly affect populations living in poverty, without 
adequate sanitation and in close contact with infectious vectors 
and domestic animals and livestock.109 
 A subset of life-threatening NTDs includes Kala azar 
(visceral leishmaniasis), sleeping sickness (African 
trypanosomiasis) and Chagas disease (American 
trypanosomiasis), Dengue, Chikungunya, river blindness 
(Onchocerciasis) which all may lead to fatal complications but 
are restricted to limited geographical areas and specific groups. Most current chemotherapeutics  
against these diseases are toxic, marginally effective and must be given by injection and become 
compromised by the development of drug-resistance. Despite the large number of people at risk 
and the substantial burden of disease, with few exceptions, no major interventions have been 
developed for generations. 80 
LEISHMANIASIS 
Leishmaniasis has been known for many hundreds of years, with one 
of the first clinical descriptions made in 1756 by Alexander Russell 
and called Aleppo boil. Many names correspond to this group of 
diseases: kala-azar, dum-dum fever, white leprosy, espundia, pian 
bois, and so on. Leishmaniases are parasitic diseases spread by the bite 
of the infected female phlebotomine sand fly (Fig.5.).78  
 
 
 
 
Figure 4 Cutaneous Leishmaniasis. 
“Jericho buttons” 
Figure 5. Phlebotomus Sandfly female 
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ETIOLOGY 
Leishmaniases are caused by infection of various species of Leishmania, a protozoan parasite of 
the family trypanosomatidae (order kinetoplastida).108The trypanosomes are characterized by 
having a single long whip-like projection known as a flagellum. Members of this group are 
parasitic, mostly on insects, but several genera have life cycles that involve alternative hosts 
including plants and vertebrates. The latter group include the species that can cause severe diseases 
in humans including Leishmaniasis (Leishmania spp), African sleeping sickness and Chagas 
disease (Trypanosoma spp.),and others.79 
 
 
 
 
 
        
 
 
Fig.6.A Trypanosoma 
Human visceral leishmaniasis is primarily caused by Leishmania donovani (which includes L. 
archibaldi) and L. infantum/ L. chagasi. L. donovani is anthroponotic it is mainly transmitted 
between people, who act as the reservoir hosts. L. infantum is zoonotic. At one time, two different 
names were used for this organism - L. infantum in the “Old World” (Eastern Hemisphere) and L. 
chagasi in the “New World” (Western Hemisphere) – and these two organisms were thought to be 
different species. As a result of genetic studies, they have been reclassified into one species, L. 
infantum. However, some authors argue that L. chagasi should be a subspecies of L. infantum, and 
the name L. chagasi is still used frequently in South America. Other organisms can occasionally 
cause visceral leishmaniasis with L. tropica and L. amazonensis, which usually cause cutaneous 
leishmaniasis, and a newly described species in Thailand, have been linked to some cases. 
Most Leishmania species cause cutaneous leishmaniasis in people. In the New World, these 
organisms include the members of the L. braziliensis complex (L. braziliensis, L. panamensis/ L. 
guyanensis, L. shawi and L. peruviana) and the L. mexicana complex (L. mexicana, L. 
amazonensis, L. venezuelensis), as well as L. lainsoni, L. naiffi and L. lindenbergi. Old World 
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species that cause cutaneous leishmaniasis include L. tropica, L. major and L. aethiopica, which 
are all members of the L. tropica complex. In addition some strains of L. infantum can cause 
cutaneous leishmaniasis without affecting the internal organs. With the exception of the 
anthroponotic species L. tropica, all of these organisms are zoonotic. The type of skin lesions, 
efficacy of treatment, speed of healing and other factors vary with the species. Most Old World 
and New World species only cause lesions on the skin, but the New World organisms                          
L. braziliensis and L. panamensis/L. guyanensis may cause either cutaneous or mucocutaneous 
leishmaniasis.108 
Classification79 
There are four major forms of human leishmaniasis. The particular presentation of the disease reflects a 
complex interplay between the individual infecting species and the host’s immune response.  
• Cutaneous leishmaniasis (CL - Baghdad ulcer, Delhi boil, Bouton d’ Orient) - is the most common form 
of the disease and produces large numbers of skin lesions that self-heal within a few months but can leave 
many unsightly and sometimes disabling scars. 
• Diffuse cutaneous leishmaniasis (DCL) – produces disseminated and chronic skin lesions that do not 
heal spontaneously and tend to relapse after treatment. 
• Mucocutaneous leishmaniasis (MCL - espundia) - begins with skin ulcers and progresses to lesions 
which cause massive tissue destruction of the mouth, nose and throat cavities and severe disfigurement. 
• Visceral leishmaniasis (VL - kala azar, black fever) – is the most serious form of the disease and causes 
death in almost 100% of the cases if left untreated. Symptoms include significant swelling of the spleen 
and liver, irregular fever episodes, substantial weight loss, decreased appetite, anemia, abdominal distension 
with splenomegaly and hepatomegaly. Progress of the disease is extremely variable. The usual duration is 
12-16 weeks, but individual cases can last from one to more than 20 weeks. People  with successfully 
treated infections continue to carry the parasite, and the disease may recur if they become immune-
supressed.    
Sometimes a secondary form of the disease called post kala-azar dermal leishmaniasis sets in a 
few months to several years after recovery from VL. The disease starts as small skin lesions on the face 
which gradually enlarge and spread over the body. The lesions may eventually form disfiguring swollen 
structures that may cause blindness if they reach the eyes. This condition is distinct from the milder 
cutaneous leishmaniasis. In India, PKDL is seen in 1-3% of successfully treated cases of visceral 
leishmaniasis. 
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Cutaneous leishmaniasis: 
 It is also known as oriental sore, tropical sore, Delhi boil, 
Baghdad ulcer, chiclero ulcer, or chiclero's ulcer is the most 
common form of leishmaniasis affecting humans. It typically 
presents as a papule that enlarges over weeks to months to form 
a shallow ulcer with raised red margins and that is thought            
( without definitive data) to ultimately self-heal with scarring 
in months to years. 
  Many lesions remain localized, but in some cases, the parasites may spread via the 
lymphatics and produce secondary lesions on the skin or occasionally the mucosa of other parts of 
the body. Regional lymphadenopathy sometimes occurs. Cutaneous leishmaniasis is usually 
painless unless the lesions become secondarily infected and except in the ear, the ulcers tend to 
remain confined to the skin and do not affect the subcutaneous tissues. Most skin lesions heal 
spontaneously  however, the speed of healing varies with the species of Leishmania. In some cases, 
it may take several months to a year or longer. Some forms leave permanent scars. HIV-infected 
individuals can have unusually severe cases, and the disease is more difficult to cure. Steroid 
treatment or other forms of immunosuppression can also result in unusually severe disease.   
 In cutaneous disease due to Leishmania braziliensis species, the ulcers may weep and the 
disease may metastasize to the proximal skin or rarely to the oronasal mucosa (muosal 
leishmaniasis).  
Disseminated leishmaniasis108 is a rare form of cutaneous disease. It is seen especially with            
L. amazonensis in the Western Hemisphere, although other organisms can also be involved. It also 
occurs in the Eastern Hemisphere, often in people who have concurrent HIV infections. In diffuse 
cutaneous leishmaniasis, the nodules do not ulcerate but they spread widely on the skin. They may 
cause damage to deep tissues, and can persist indefinitely. The diffuse form can be incurable in 
some cases.  
Leishmaniasis recidivans108 (lupoid leishmaniasis), another rare form, is characterized by the 
development of new lesions around the edges of a healed skin lesion. It is most often caused by      
L tropica or L braziliensis and it does not heal without treatment. 
Figure 7. A Delhi boil 
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Although cutaneous leishmaniasis results in morbidity rather than in mortality, such   patients are 
generally treated because of the local morbidity and the possibility of metastasis.  
VARIOUS STAGES OF LIFE CYCLE OF LEISHMANIASIS 
Leishmania spp. are digenetic or heteroxenous parasites, whose life cycle involves two hosts, a 
vertebrate and an invertebrate, the sandfly. Hemoflagellates may have several morphological 
stages that differ from one another in the placement of the kinetoplast relative to the nucleus, as 
well as the location and origin of the flagellum. Leishmania exist in two basic body forms, the 
amastigote, the intracellular form in the vertebrate host and the promastigote, the extracellular 
form in the sandfly (Phleobotomus spp. and Lutzomyia spp) vector. Amastigotes are taken up from 
the blood of an infected host when the female sandfly bites and in the sand-fly gut they develop 
into promastigotes where they multiply by binary fission, pro-mastigotes move anteriorly into the 
proboscis and are introduced into the vertebrate host when the sand-fly bites again. The 
Figure 5. stages of Life cycle in Leishmaniasis( courtesy CDC.gov) 
Figure 8 stages of life cycle - Leishmania spp 
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promastigotes injected by the sand-fly during feeding are phagocytized and develop into 
intracellular amastigotes. 
  The amastigote, literally “without a flagellum,” is the intracellular, non-motile form in the 
vertebrate host and it divides by longitudinal binary fission at 37oC. Intracellular amastigotes are 
3-6 um in length and 1.5-3.0 um in width. The amastigote is also called the Leishman-Donovan 
(LD) body. The amastigote is not really devoid of a flagellum, it is simply that the flagellum does 
not protrude beyond the body surface and by light microscopy cannot be seen. 
The promastigote, literally the body form with “an anterior flagellum” is 15-30 um in body length 
and 5mm in width; it is extracellular, motile, and grows and divides by longitudinal binary fission 
at 27oC in the sand-fly. Promastigotes can be grown in- vitro at 25oC temperature on NNN medium, 
which has a solid phase of blood agar and a liquid phase containing a physiologic salt solution. 
Liquid media that support promastigote growth are also available. Amastigotes usually are grown 
inside tissue culture cells and can also be grown extra-cellularly at 37oC under special 
conditions.108 
Note: Most Leishmania species are maintained by an animal-to-animal transmission cycle and 
humans are considered an accidental host. However, anthroponotic transmission without animal 
reservoirs is also reported in some Leishmania species. 
Figure 9. Morphological forms of Leishmania 
     Disease Profile… 
Department of Pharmaceutics, COP, MMC Page 64 
 
The transformation from amastigote to promastigote in the gut of the sandfly is triggered by a 
change in conditions such as temperature and pH. The main target of the parasite in mammalian 
hosts is macrophages, and infections are known to occur in three ways (1) direct infection, (2) 
phagocytosis of infected neutrophils by macrophages (the Trojan horse model) and 3) silent 
infection by parasites released from apoptotic neutrophils. Neutrophils which are recruited to sites 
of tissue damage caused by sand fly bites in the initial phase, are considered to ingest the majority 
of parasites and play a central role in the establishment of the Leishmania infection .103 
Communicability108 
Leishmaniasis is usually vector-borne, but person-to-person transmission including vertical 
(congenital) transmission, venereal transmission, and transmission by blood transfusion has been 
reported. Newborns can be infected whether or not the mother was symptomatic. Humans infected 
with some species of Leishmania can infect sandflies. 
 
Figure 10 Trojan Horse Hypothesis.110 
     Disease Profile… 
Department of Pharmaceutics, COP, MMC Page 65 
 
Transmission108 
Leishmania spp are usually transmitted indirectly between hosts by sandflies of the genera 
Phlebotomus and Lutzomyia, which are biological vectors. Each species of Leishmania is adapted 
to transmission in certain species of sandflies. Only the females feed on blood. Sandfly activity 
occurs when it is humid, and there is no wind or rain. These insects are usually most active at 
dawn, dusk and during the night, but they will bite if they are disturbed in their hiding places 
(animal burrows, holes in trees, caves, houses and other relatively cool, humid locations) during 
the day. They are attracted to light and may enter buildings at night. 
Other arthropods including ticks (Dermacentor variabilis and Rhipicephalus sanguineus) and 
canine fleas may also act as mechanical vectors. Where sandflies transmit Leishmania spp., ticks 
and fleas are probably unimportant in the epidemiology of the disease, however they might be 
involved in rare cases of dog-to-dog transmission in other locations. 
These parasites have also been transmitted via blood transfusions in people and dogs and 
by transplacental transmission in dogs, mice and humans. In canine leishmaniasis caused by L. 
infantum, the parasites can sometimes be found in saliva, urine, semen and conjunctival secretions, 
as well as in blood. 
Diagnostic tests108 
Cutaneous leishmaniasis can be diagnosed by direct observation of the parasites in skin scrapings, 
impression smears or skin biopsies stained with Giemsa, Leishman’s, Wright’s or other stains. 
Amastigotes are easiest to find in recent or active lesions. Polymerase chain reaction assays (PCR) 
are often used for diagnosis in areas where they are available. Leishmania spp can also be cultured. 
However, each species will grow only in certain media and some species can be difficult to isolate. 
Novy-MacNeil-Nicole (NMN) medium, brain–heart infusion (BHI) medium, Evan’s modified 
Tobie’s medium (EMTM), Grace’s medium and Schneider’s Drosophila medium might be used 
initially. Animal inoculation into hamsters may also be valuable, especially with contaminated 
material. Diagnosing leishmaniasis by in vitro culture requires 5 to 30 days, while animal 
inoculation can take weeks or months. The species, subspecies and/or strain can be identified by 
PCR, DNA hybridization, kinetoplast DNA restriction endonuclease analysis, isoenzyme analysis 
or immunological techniques that use monoclonal antibodies. A delayed hypersensitivity test, the 
leishmanin skin test (Montenegro skin test), is useful in the diagnosis of cutaneous and 
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mucocutaneous leishmaniasis, but it is usually negative in the diffuse cutaneous form. Antibodies 
are often slow to develop and of low titer. 
Disinfection 108 
Leishmania spp do not remain viable outside a host or in vitro culture. They can be inactivated by 
1% sodium hypochlorite, 2% glutaraldehyde or formaldehyde. They are also susceptible to heat of 
50–60°C. 
Treatment 108 
Visceral or cutaneous leishmaniasis can usually be cured in immunocompetent individuals. 
Pentavalent antimonials can be used where the parasites are sensitive to these drugs, but resistance 
is a major problem in some areas. Other drugs such as allupurinol, amphotericin B or liposomal 
amphotericin B, and miltefosine may also be used. Most of the drugs used to treat leishmaniasis 
must be given parenterally. Visceral leishmaniasis in AIDS patients is often resistant to treatment, 
and many patients relapse.  
Cutaneous leishmaniasis may be treated to speed healing, decrease scarring and decrease the risk 
of mucosal disease or relapse. Intralesional, topical or systemic drugs may be used, depending on 
the species of Leishmania and the risk of more serious complications. Cryotherapy, thermotherapy, 
or curettage have also been employed in some cases. Some cutaneous leishmaniasis lesions that 
are improving may simply be observed, if they are caused by relatively benign organisms. Mucosal 
leishmaniasis is a serious condition and it is treated with systemic drugs. 
Prevention108 
Preventive measures against sandflies include 
 using insect repellents such as DEET 
 covering exposed skin 
 staying on higher floors of buildings in the evening or at night, as these insects are poor 
fliers.  
 Fans can also be helpful, and insecticidal sprays can be used to kill the insects inside 
houses.  
 Insecticide-treated bed nets decrease bites from these insects at night.  
 Insecticide spraying programs have been conducted in some countries.  
Treatment of human patients may be helpful in areas where anthroponotic transmission is 
important. Decreasing the incidence of L. infantum in dogs can help protect people from this 
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organism. Some studies have shown that insecticide impregnated dog collars protected both dogs 
and children in areas where they were used. Infected dogs have been culled in some countries.  The 
only practical way to decrease the incidence of these disease is personal protection with insect 
repellents and other measures.  
Drugs in lead optimization and preclinical phases76 
Plant products are an abundant source of leads, evidenced in the area of anti-malarials. 
Licochalcone A from the Chinese Liquorice plant glycyrrhiza has shown reasonable oral efficacy 
in experimental models of VL and CL.      
Another compound PX-6581 from the Vietnamese plant Maesa balansae showed 
significant activity in VL models but was not progressed due to toxicity. Isopropyl quinolines 
isolated from Galipea longiflora in Bolivia also showed activity in VL and CL models and studies 
on further SAR have recently been published. 
Therapeutic switching or “piggy-back chemotherapy” is another potential source for new 
antileishmanial compounds. Azoles, originally developed as antifungal drugs have shown activity 
against Leishmania spp. Like fungi, Leishmania synthesize 24-substituted sterols, such as 
ergosterol (mammals have cholesterol). Azoles can inhibit a key enzyme of this pathway,             
14α-demethylase. Ketoconazole, itraconazole and fluconazole have given equivocal results in 
trials against both CL and VL. Bisphosphonates, used for the treatment of bone disorders such as 
osteoporosis, are another example of therapeutic switching. Two of these drugs, risedronate and 
pamidronate, were active against experimental infections of both CL and VL. 
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Drug name  : Ketoconazole 122 
Brand name  : Extina, Nizoral, Ketozole, Xolegel, Fungrest, ketoderm, ketozoral 
IUPAC name122 : 1-[4-(4-{[(2R,4S)-2-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-
ylmethyl)-1,3-dioxolan -4-yl] methoxy}phenyl) piperazin-1-yl] 
ethan-1-one. 
CAS number  : 65277-42-1 
Formula  : C26H28Cl2N4O4 
Molecular weight  : 531.4 g/mol 
Physical form  : A White to off-white crystalline powder 
Odour  : Odourless 
Melting range  : 148°C  to 152°C 
Structure:  
 
 
 
 
 
 
 
Solubility49 : Freely soluble in Dichloromethane, soluble in chloroform and in 
methanol, sparingly soluble in ethanol (95 percent), practically 
insoluble in water and in ether.  
Figure 11.  Structure of Ketoconazole. 
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CLINICAL PHARMACOLOGY  
Pharmacokinetics  
Mean peak plasma levels of approximately 3.5 μg/ml are reached within 1 to 2 hours, 
following oral administration of a single 200 mg dose taken with a meal. Subsequent plasma 
elimination is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter. 
Following absorption from the gastrointestinal tract, Ketoconazole
 
is converted into several 
inactive metabolites. The major identified metabolic pathways are oxidation and degradation of 
the imidazole and piperazine rings, oxidative dealkylation and aromatic hydroxylation. About 13% 
of the dose is excreted in the urine of which 2 to 4% is unchanged drug. The major route of 
excretion is through the bile into the intestinal tract. In vitro plasma protein binding is about 99% 
mainly to the albumin fraction. Only a negligible proportion of Ketoconazole reaches the 
cerebrospinal fluid. Ketoconazole is a weak dibasic agent and thus requires acidity for dissolution 
and absorption.  
Electrocardiogram  
Pre-clinical electrophysiological studies have shown that Ketoconazole inhibits the rapidly 
activating component of the cardiac delayed rectifier potassium current, prolongs the action 
potential duration and may prolong the QTc interval. Data from some clinical PK/PD studies and 
drug interaction studies suggest that oral dosing with Ketoconazole at 200 mg twice daily for 3-7 
days can result in an increase of  the QTc interval, a mean maximum increase of about 6 to 12 
msec was seen at Ketoconazole peak plasma concentrations about 1-4 hours after Ketoconazole 
administration.  
Mechanism of Action  
Ketoconazole blocks the synthesis of ergosterol, a key component of the fungal cell 
membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-
demethylase responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane. 
This results in an accumulation of methylated sterol precursors and a depletion of ergosterol within 
the cell membrane thus weakening the structure and function of the fungal cell membrane.  
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Activity In Vitro & In Vivo  
Ketoconazole is active against clinical infections with Blastomyces dermatitidis, 
Coccidioides immitis, Histoplasma capsulatum, Paracoccidioides brasiliensis,Leishmania 
braziliensis.  
 
CONTRAINDICATIONS 
Drug Interactions  
Co-administration of a number of CYP3A4 substrates is contraindicated with 
Ketoconazole. Co-administration with Ketoconazole can cause elevated plasma concentration of 
these drugs and may increase or prolong both therapeutic and adverse effects. For example, 
increased plasma concentration of some of these drugs can lead to QTc prolongation and 
ventricular tachyarrhythmias including occurrence of torsades de pointes, a potentially fatal 
arrhythmia.  
Liver Disease  
The use of Ketoconazole is contraindicated in patients with acute or chronic liver disease.  
Hypersensitivity It 
 
is contraindicated in patients who have shown hypersensitivity to the drug.  
WARNINGS  
Ketoconazole should be used only when other effective antifungal therapy is not available 
or tolerated and the potential benefits are considered to outweigh the potential risks.  
Hepatotoxicity  
Serious hepatotoxicity including cases with a fatal outcome or requiring liver 
transplantation has occurred with the use of oral Ketoconazole. Some patients had no obvious risk 
factors for liver disease. Serious hepatotoxicity was reported both by patients receiving high doses 
for short treatment durations and by patients receiving low doses for long durations. The hepatic 
injury has usually but not always been reversible upon discontinuation of Ketoconazole treatment. 
Cases of hepatitis have been reported in children.  
At baseline, obtain laboratory tests (such as SGGT, alkaline phosphatase, ALT, AST, total 
bilirubin (TBL), Prothrombin Time (PT), International Normalization Ratio (INR) and testing for 
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viral hepatitides). Patients should be advised against alcohol consumption while on treatment. If 
possible, use of other potentially hepatotoxic drugs should be avoided in patients receiving 
Ketoconazole .  
Prompt recognition of liver injury is essential. During the course of treatment, serum ALT 
should be monitored weekly for the duration of treatment. If ALT values increase to a level above 
the upper limit of normal or 30 percent above baseline or if the patient develops symptoms, 
ketoconazole treatment should be interrupted and a full set of liver tests should be obtained. Liver 
tests should be repeated to ensure normalization of values. Hepatotoxicity has been reported with 
restarting oral Ketoconazole (rechallenge). If it is decided to restart oral Ketoconazole monitor 
the patient frequently to detect any recurring liver injury from the drug.  
QT Prolongation and Drug Interactions Leading to QT Prolongation  
Ketoconazole can prolong the QT interval. Co-administration of the following drugs with 
Ketoconazole is contraindicated to dofetilide, quinidine, pimozide, and cisapride. Ketoconazole 
can cause elevated plasma concentrations of these drugs which may prolong the QT interval, 
sometimes resulting in life threatening ventricular dysrhythmias such as torsades de pointes.  
Adrenal Insufficiency  
Ketoconazole Tablets decrease adrenal corticosteroid secretion at doses of 400 mg and 
higher. This effect is not shared with other azoles. The recommended dose of 200 mg - 400 mg 
daily should not be exceeded.  
Adrenal function should be monitored in patients with adrenal insufficiency or with 
borderline adrenal function and in patients under prolonged periods of stress (major surgery, 
intensive care, etc).  
Adverse Reactions Associated with Unapproved Uses  
Ketoconazole has been used in high doses for the treatment of advanced prostate cancer 
and for Cushing’s syndrome when other treatment options have failed. The safety and 
effectiveness of Ketoconazole have not been established in these settings and the use of 
Ketoconazole for these indications is not approved by FDA.  
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In a clinical trial involving 350 patients with metastatic prostatic cancer, eleven deaths were 
reported within two weeks of starting treatment with high doses of Ketoconazole tablets (1200 
mg/day). It is not possible to ascertain from the information available whether death was related 
to Ketoconazole therapy or adrenal insufficiency in these patients with serious underlying disease.  
Hypersensitivity  
Anaphylaxis has been reported after the first dose. Several cases of hypersensitivity reactions 
including urticaria have also been reported.  
Enhanced Sedation  
Co-administration of oral Ketoconazole with oral midazolam, oral triazolam or alprazolam has 
resulted in elevated plasma concentration of these drugs. This may potentiate and prolong 
hypnotic and sedative effects, especially with repeated dosing or chronic administration of these 
agents. Concomitant administration of Ketoconazole tablets with oral triazolam, oral midazolam 
or alprazolam is contraindicated. 
Myopathy  
Co-administration of CYP3A4 metabolized HMG-CoA reductase inhibitors such as simvastatin, 
and lovastatin is contraindicated with Ketoconazole
 
tablets.  
PRECAUTIONS 
General  
Ketoconazole tablets have been demonstrated to lower serum testosterone. Once therapy with 
Keoconazole
 
tablets has been discontinued, serum testosterone levels return to baseline values. 
Testosterone levels are impaired with doses of 800 mg per day and abolished by 1600 mg per 
day. Clinical manifestations of decreased testosterone concentration may include gynecomastia, 
impotence and oligospermia.  
Information for Patients  
Patients should be instructed to report any signs and symptoms which may suggest liver 
dysfunction so that appropriate biochemical testing can be done. Such signs and symptoms may 
include unusual fatigue, anorexia, nausea and/or vomiting, abdominal pain, jaundice, dark urine 
or pale stools.  
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Drug Interactions  
Drugs that affect the absorption, distribution, metabolism and excretion of Ketoconazole may 
alter the plasma concentration of Ketoconazole. For example gastric acid suppressants (e.g., 
antacids, histamine H2-blockers, proton pump inhibitors) have been shown to reduce plasma 
concentration of Ketoconazole. Ketoconazole is a substrate and potent inhibitor of CYP3A4. 
Therefore, the following drug interactions may occur when Ketoconazole
 
is co-administered with 
other drugs that interact with CYP3A4.  
1. Ketoconazole may decrease the elimination of drugs metabolized by CYP3A4, thereby increasing 
their plasma concentration. Increased exposure to these drugs may cause an increase or 
prolongation of their therapeutic and/or adverse effects. Concomitant use with Ketoconazole
 
tablets is contraindicated for drugs known to present a risk of serious side effects with increased 
exposure. For others, monitoring of plasma concentration is advised when possible. Clinical signs 
and symptoms associated with these drugs should be monitored with dosage adjusted as needed.  
2. Inducers of CYP3A4 may decrease the plasma concentration of Ketoconazole. Ketoconazole
 
may 
not be effective in patients concomitantly taking one of these drugs. Therefore, administration of 
these drugs with Ketoconazole
 
is not recommended.  
3.  Other inhibitors of CYP3A4 may increase the plasma concentration of  Ketoconazole. Patients 
who must take Ketoconazole
 
concomitantly with one of these drugs should be monitored closely 
for signs or symptoms of increased or prolonged pharmacological effects of Ketoconazole. 
Carcinogenesis, Mutagenesis, Impairment of Fertility  
Ketoconazole did not show any signs of mutagenic potential when evaluated using the 
dominant lethal mutation test or the Ames Salmonella microsomal activator assay. Ketoconazole was 
not carcinogenic in an 18-month, oral study in Swiss albino mice or a 24-month oral carcinogenicity 
study in Wistar rats at dose levels of 5, 20 and 80 mg/kg/day. The high dose in these studies was 
approximately 1times the clinical dose in humans for mouse or 2 times the clinical dose in humans for 
rats based ona mg/m2  comparison.  
Pregnancy  
Teratogenic effects: Pregnancy Category C: Ketoconazole has been shown to be teratogenic 
(syndactylia and oligodactylia) in the rat when given in the diet at 80 mg/kg/day (2 times the maximum 
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recommended human dose, based on body surface area comparisons). However, these effects may be 
related to maternal toxicity, evidence of which also was seen at this and higher dose levels.  
There are no adequate and well controlled studies in pregnant women. Ketoconazole tablets should be 
used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  
Nonteratogenic Effects  
Ketoconazole has also been found to be embryotoxic in the rat when given in the diet at 
doses higher than 80 mg/kg during the first trimester of gestation. In addition, dystocia (difficult 
labor) was noted in rats administered with oral Ketoconazole during the third trimester of gestation. 
This occurred when Ketoconazole was administered at doses higher than 10 mg/kg (about one fourth 
the maximum human dose, based on body surface area comparison).  
Nursing Mothers  
Ketoconazole has been shown to be excreted in the milk. Mothers who are under treatment with 
Ketoconazole tablets should not breast feed.  
Pediatric Use  
Ketoconazole Tablets have not been systematically studied in children of any age and essentially no 
information is available on children under 2 years. Ketoconazole tablets should not be used in pediatric 
patients unless the potential benefit outweighs the risks.  
ADVERSE REACTIONS  
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed 
in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug 
and may not reflect the rates observed in practice.  
The following adverse reactions were reported in clinical trials:  
 Immune System Disorders: anaphylactoid reaction. 
  Endocrine Disorders: gynecomastia. 
  Metabolism and Nutrition Disorders: alcohol intolerance, anorexia, hyperlipidemia, 
increased appetite. 
  Psychiatric Disorders: insomnia, nervousness. 
  Nervous System Disorders: headache, dizziness, paresthesia, somnolence. 
  Eye Disorders: photophobia; 
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 Vascular Disorders: orthostatic hypotension  
 Respiratory disorders: 
 Thoracic and Mediastinal Disorders: epistaxis;  
 Gastrointestinal Disorders: vomiting, diarrhea, nausea, constipation, abdominal pain, 
abdominal pain upper, dry mouth, dysgeusia, dyspepsia, flatulence, tongue discoloration; 
  Hepatobiliary Disorders: hepatitis, jaundice, hepatic function abnormal; 
  Skin and Subcutaneous Tissues Disorders: erythema multiforme, rash, dermatitis, 
erythema, urticaria, pruritus, alopecia, xeroderma. 
 Musculoskeletal and Connective Tissue Disorders: myalgia; 
  Reproductive System and Breast Disorders: menstrual disorder; General Disorders and 
Administration Site Conditions: asthenia, fatigue, hot flush, malaise, edema peripheral, 
pyrexia, chills;  
 Investigations: platelet count decreased. 
OVERDOSAGE  
In the event of acute accidental overdose, treatment consists of supportive and symptomatic measures. 
Within the first hour after ingestion, activated charcoal may be administered.  
DOSAGE AND ADMINISTRATION  
There should be laboratory as well as clinical documentation of infection prior to starting Ketoconazole 
therapy. The usual duration of therapy for systemic infection is 6 months. Treatment should be 
continued until active fungal infection has subsided.  
Adults  
The recommended starting dose of (Ketoconazole) tablets is a single daily administration of 200 mg 
(one tablet). If clinical responsiveness is insufficient within the expected time, the dose may be 
increased to 400 mg (two tablets) once daily.  
 
Children  
In small number of children over 2 years of age, a single daily dose of 3.3 to 6.6 mg/kg  
has been used. Ketoconazole 
 
tablets have not been studied in children under 2 years of age. 
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INDICATIONS AND USAGE  
Ketoconazole should be used only when other effective antifungal therapy is not available or 
tolerated and the potential benefits are considered to outweigh the potential risks.  
It is indicated for the treatment of the following systemic fungal infections in patients who 
have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, 
histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole should not be used 
for fungal meningitis because it penetrates poorly into the cerebrospinal fluid.  
Orally administered Ketoconazole is effective in dermatophytosis because it is 
concentrated in the stratum comeum; is an altemative to griseofulvin, but use is restricted due to 
potential adverse effects. Though effective in monilial vaginitis, oral therapy (for 5-7 days) with 
Ketoconazole is reserved for recurrent cases or those not responding to topical agents. 
Systemic mycosis: Administered orally, Ketoconazole is effective in several types of systemic 
mycosis, but itraconazole and fluconazole, being more active with fewer side effects, have largely 
replaced it for these indications except for considerations of cost. Ketoconazole is occasionally 
used in dermal leishmaniasis and kala azar. High-dose Ketoconazole has been used in Cushing's 
syndrome to decrease corticosteroid production. 123 
7. EXCIPIENT PROFILE 
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 SORBITAN MONOLAURATE 20125-127  
SYNONYM 
Arlacel 20; Emsorb 515; SPAN(R) 20; Arlasel 20; Dehymuls SML; E493; Glycomul L; 
Hodag SML; Liposorb L; Montane 20; Protachem SML; Sorbester P12; 
Sorbirol L; sorbitan laurate; Span 20; Tego SML 
IUPAC NAME127 
  [(2R) – 2- [(3R,4S)-3,4- dihydroxyoxolan–2–yl]-2-hydroxy ethyl] dodecanoate. 
EMPIRICAL FORMULA 
 C18H34O6 
MOLECULAR WEIGHT 
  346.47 g/mol 
STRUCTURE             
 
Figure 12 Sorbitan monolaurate 
DESCRIPTION 
 Amber to brown oily liquid. 
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PROPERTIES 
 Density – 1.032 g/ml at 25° C.(lit.) 
 Hydroxyl value- 330-358 mg KOH/g 
 Saponification value- 158-170 mg KOH/g 
 Acid value ≤ 1.5% 
 Melting point- >200°C 
 Boilingpoint  516.1°C at 760 mmHg. 
 Flash point – 176.9°C 
 HLB value- 8.6 
 Solubility – slighty soluble in isopropanol, tetracarp,xylene, cotton seed oil and mineral 
oil. Slightly soluble in liquid paraffin and insoluble in water.         
FUNCTIONAL CATEGORY 
 Emulsifying agent 
 Non- ionic surfactant 
 Lubricant 
 Wetting agent 
 Dispersing/ Suspending agent 
STORAGE 
  It should be stored in a well- closed container in a cool, dry place. 
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SORBITAN MONOPALMITATE48 
SYNONYMS 
Arbunol S-40; Alracel 40; Crill 2; Liposorb P; Montane 40; Sorbitan palmitate; Span 40. 
CHEMICAL NAME 
Sorbitan Mono Hexadecanoate 
EMPIRICAL FORMULA 
 C22H42O6 
MOLECULAR WEIGHT 
 403 
STRUCTURE 
 
Figure 13 Sorbitan Monopalmitate 
DESCRIPTION 
 Creamy solid 
PROPERTIES 
 Acid value- 3- 7 
 Hydroxyl value- 270- 303 
 Saponification value- 142- 152 
 Melting point- 43- 48°C 
Excipient Profile… 
 
 
Department of Pharmaceutics, COP, MMC Page 80 
 
 
 Density (g/cm3)- 1.0 g/cm3 
 HLB value- 6.7 
FUNCTIONAL CATEGORY 
 Emulsifying agent 
 Non- ionic surfactant 
 Solubiizing agent 
 Wetting agent 
 Dispersing/ Suspending agent 
STABILITY 
 Gradual soap formation occurs with strong acids or bases 
 Stable in weak acids or bases. 
STORAGE 
 It should be stored in a well- closed container in a cool, dry place. 
SAFETY 
 Daily intake according to the WHO limit is about 25 mg/ kg body weight. 
HANDLING PRECAUTIONS 
 Eye protection and Gloves are recommended. 
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SORBITAN MONOSTEARATE48 
SYNONYM 
Arbunol S- 60; Alracel 60; Crill 3; Liposorb S-K; Montane 60; Sorbitan stearate; Span 
60; Tego SMS. 
CHEMICAL NAME 
 Sorbitan Mono- Octadecanoate  
EMPIRICAL FORMULA 
 C24H46O6 
MOLECULAR WEIGHT 
 431 
STRUCTURE 
 
Figure 14 Sorbitan monostearate 
DESCRIPTION 
 Cream solid 
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PROPERTIES 
 Acid value- 5- 10 
 Hydroxyl value- 235- 260 
 Saponification value- 147- 157 
 Melting point- 53- 57°C 
 HLB value- 4.7 
FUNCTIONAL CATEGORY 
 Emulsifying agent 
 Non- ionic surfactant 
 Solubilizing agent 
 Wetting agent 
 Dispersing/ Suspending agent 
STABILITY 
 Gradual soap formation occurs with strong acids or bases 
 Stable in weak acids or bases. 
STORAGE 
 It should be stored in a well- closed container in a cool, dry place. 
SAFETY 
 Daily intake according to the WHO limit is about 25 mg/ kg body weight. 
HANDLING PRECAUTIONS 
 Eye protection and Gloves are recommended. 
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CHOLESTEROL48 
SYNONYM 
 Cholesterolum; Cholesterin 
CHEMICAL NAME 
 Cholest- 5-en-3β- ol 
EMPIRICAL FORMULA 
 C27H46O 
MOLECULAR WEIGHT 
 386.67 
STRUCTURE 
 
Figure 15. Cholesterol 
 
FUNCTIONAL CATEGORY 
 Emulsifying agent 
 Emollient 
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DESCRIPTION 
 Cholesterol occurs as white or faintly yellow, almost odourless, pearly leaflets, needles, 
powder or granules. 
 On prolonged exposure to light and air, it acquires a yellow to tan colour. 
PROPERTIES 
 Boiling point- 360°C 
 Density- 1.052 g/ cm3 for anhydrous form 
 Melting point- 147- 150°C 
 Solubility – soluble in acetone and vegetable oils, Practically insoluble in water, 
Soluble in chloroform: methanol mixture. 
STABILITY AND STORAGE CONDITIONS 
 It is stable, and should be stored in a well- closed container and protected from light. 
SAFETY 
It is generally regarded as an essentially non- toxic and non- irritant material at the levels 
employed as an excipients. 
HANDLING PRECAUTIONS 
 Rubber or plastic gloves, eye protection and a respirator are recommended. 
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CARBOPOL 940128,129,130. 
NON-PROPRIETARY NAME:  
 BP- Carbomers, PhEur- Carbomera, USPNF- Carbomer. 
SYNONYMS: 
 Acritamer; acrylic acid polymer; Carbopol; Carboxy Polymethylene; Polyacrylic acid; 
Carboxyvinyl polymer; Pemulen; Ultrez.    
CHEMICAL NAME 
 Poly (acrylic acid) 
IUPAC NAME 
Prop-2- enoic acid 
EMPIRICAL FORMULA 
 (C3H4O2)n 
MOLECULAR WEIGHT 
 Variable. For Carbopol 940, M.W = 940. 
CAS NUMBER: 9003-01-4 
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STRUCTURE 
 
 
FUNCTIONAL CATEGORY 
 Bioadhesive, Emulsifying agent, release-modifying agent, suspending agent, tablet-
binder, viscosity increasing agent. 
 Carbopol 940 polymer is an extremely efficient rheology modifier capable of providing 
high viscosity and forms sparkling clear water or hydro-alcoholic gels and creams.   
DESCRIPTION 
 Carbomers are white-colored, ’fluffy’, acidic, hygroscopic powders with a slight 
characteristic odour. 
PROPERTIES 
 Boiling point- 116°C. 
 Density- 1.2 g/ ml at 25°C. 
 Flash point: 100°C 
 Melting point- 12.5°C.129 
 Solubility – soluble in water and ethanol. 
Figure 16. carbopol  
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STABILITY AND STORAGE CONDITIONS 
 It is hygroscopic, and should be stored in a well- closed container and protected 
from moisture.  
SAFETY STATEMENT 
Moderately toxic by ingestion. when heated to decomposition it emits acrid smoke and 
irritating vapors. 
 
8. MATERIALS AND METHODS 
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The list of drug, excipients used and their manufacturer are show in Table  
Table 1: List of Materials Used 
S. No. DRUG/ EXCIPIENT MANUFACTURER/ SUPPLIER 
1 Ketoconazole USP 
East West Pharma, Haridwar, 
Uttarakhand-247661. 
2 Cholesterol S.D. Fine chem. Ltd 
3 Sorbitan Monopalmitate SPAK Orgochem India Pvt Ltd 
4 Sorbitan Monostearate SPAK Orgochem India Pvt Ltd 
5 Sorbitan Monolaurate Lab chemicals Ltd 
6 Carbopol 940 
East West Pharma, Haridwar, 
Uttarakhand-247661. 
6 Sodium chloride Indian research products 
7 Potassium dihydrogen ortho phosphate Nice chemicals Pvt Ltd 
8 Disodium hydrogen ortho phosphate Indian research products 
9 Chloroform Merck specialities Pvt Ltd 
10 Methanol Sisco research laboratories Pvt Ltd 
11 n-propanol Lab Chemicals Ltd 
12 Dialysis Membrane 50 Himedia 
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The list of equipments used in the study and their manufacturer are shown in Table  
Table 2: List of Equipments 
S.No EQUIPMENTS MANUFACTURER 
1 Rotary flash evaporator Equitron 
2 Ultra Sonicator Lark  
3 Electronic balance 
Model No.- Jewel- 3 
Eagle  
4 Magnetic stirrer with hot plate Eltek Magnetic Stirrers 
5 UV- Visible Spectrophotometer 
SHIMADZU 
UV- 1800 
6 High speed Cooling centrifuge Remi  
7 Binocular microscope Olympus  
8 Malvern zeta sizer Malvern, Germany 
9 Scanning electron microscope Hitachi, Japan 
10 FT- IR Spectrophotometer Nicolet, India 
11 Refrigerator Whirlpool  
12 BOD incubator MC Dalal 
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METHODOLOGY 
PREPARATION OF PHOSPHATE BUFFERED SALINE (PBS) pH 7.449 
2.38 g of disodium hydrogen phosphate, 0.19 g of potassium dihydrogen phosphate and 
8.0 g of sodium chloride were dissolved in sufficient quantity of distilled water and the volume 
made up to 1000 ml. 
DRUG EXCIPIENT COMPATIBILITY STUDIES50,117 
The possibilities of drug- excipients (cholesterol, nonionic surfactant) interactions were 
investigated by FT- IR spectrum study. The FT- IR spectrum of pure drug and combination of 
drug with excipients were recorded. 
The spectrum was recorded in the wavelength region of 4000 to 400 cm-1. 
STANDARD CURVE FOR KETOCONAZOLE50 
100 mg of Ketoconazole was accurately weighed and dissolved in a small quantity of 
methanol and made up to 100 ml with methanol. From this primary solution, 10 ml was pipetted 
out and made up to 100 ml with phosphate buffered saline pH 7.4. From this secondary solution 
aliquots were taken to produce concentration of 2, 4, 6, 8, 10 µg/ ml. The absorbance of the 
resulting solution was measured at 225 nm in the UV- Visible Spectrophotometer (Shimadzu) 
using phosphate buffered saline pH 7.4 with little methanol as blank. The standard curve was 
plotted taking concentration in X- axis and absorbance in Y- axis. 
FORMULATION OF KETOCONAZOLE NIOSOMES35, 50,100 
The niosomal formulations were prepared by thin film hydration technique. Accurately 
weighed quantities of drug, non- ionic surfactant (Span 20, 40, 60) and cholesterol were 
dissolved in sufficient quantity of solvent mixture (Chloroform: Methanol 2:1) to give a clear 
solution. The resulting solution is poured into a 1000 ml rotary flask and evaporated under 
vacuum (20- 25mm Hg) at 60°±2°C with the rotation speed of 100 rpm to form a uniform thin 
dry film. The rotary flask was removed from the bath and allowed to return to room 
temperature. The thin film formed was hydrated with 20 ml of distilled water while rotating 
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the flask at 50 rpm (gentle agitation) at a temperature 60°±2°C. The resulting niosomal 
suspension was stored in a tightly closed container in a refrigerator. 
Table 3: Formulation Code of Niosomes 
FORMULATION 
CODE 
NON- IONIC 
SURFACTANT 
DRUG: SURFACTANT: 
CHOLESTEROL 
(m moles) 
KTZ 20- 1 
SPAN 20 
1:1:1 
KTZ 20- 2 1:2:1 
KTZ 20- 3 1:3:1 
KTZ 20- 4 1:4:1 
KTZ 20- 5 1:5:1 
KTZ 40- 1 
SPAN 40 
1:1:1 
KTZ 40- 2 1:2:1 
KTZ 40- 3 1:3:1 
KTZ 40- 4 1:4:1 
KTZ 40- 5 1:5:1 
KTZ 60- 1 
SPAN 60 
1:1:1 
KTZ 60- 2 1:2:1 
KTZ 60- 3 1:3:1 
KTZ 60- 4 1:4:1 
KTZ 60- 5 1:5:1 
 
In the Drug: Surfactant: Cholesterol ratio, 1 stands for 25 µmol. 
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OPTIMIZATION OF PROCESS- RELATED VARIABLES 
Effect of hydration time100, 131 
The niosomal formulations containing Span 40 at different ratios and a fixed amount 
of cholesterol (1:1:1, 1:2:1) were hydrated with 10 ml of distilled water for 30 minutes, 60 
minutes and 90 minutes. The vesicle formation and entrapment efficiency of the formulations 
were calculated by centrifugation method. 
Effect of capacity and rotational speed of evaporator flask100, 131 
The thickness and uniformity of the film depends upon the rotational speed of the 
evaporator flask. The niosomal formulations were subjected to various speeds i.e. 50 rpm, 100 
rpm and 150 rpm. The appearance of the film was checked by visual observation. 
Effect of Sonication time100, 131 
The Niosomal formulations containing Span 40 at different ratios and a fixed 
amount of Cholesterol (1:1, 2:1, 3:1, 4:1, 5:1) were subjected to ultrasonic vibration using 
Ultrasonicator. To study the effect of sonication time, the formulations were subjected to 
sonication for various time intervals (1 min, 2 mins, 3 mins, 4 mins and 5 mins). The 
entrapment efficiency of the formulations were measured.    
Effect of osmotic shock 23,100 
The effect of osmotic shock on niosomal formulations was investigated by monitoring 
the change in vesicle diameter after incubation of niosomal suspension in media of different 
tonicity i.e., 1.6% NaCl (hypertonic), 0.9% NaCl (isotonic) and 0.5% NaCl (hypotonic). 
Suspensions were incubated in these media for 3 hours and the change in vesicle size was 
measured by optical microscopy with a calibrated eyepiece micrometer. 
CHARACTERIZATION OF NIOSOMES 
PARTICLE SIZE ANALYSIS45,100 
The Niosomal suspension was diluted, filled in a cuvette using suitable blank and the 
average vesicle size of the Niosomes was determined using Malvern zeta sizer. 
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DRUG CONTENT ANALYSIS6,50,100 
The amount of drug in the formulation was determined by lysing the niosomes using 
50% n-propanol. 1 ml of the niosomal preparation was pipetted out, sufficient quantity of 50% 
n-propanol was added and shaken well for the complete lysis of the vesicles. After suitable 
dilution with the phosphate buffered saline of pH 7.4 containing 10% Methanol, the absorbance 
of the solution was measured at 225 nm in the UV- Visible Spectrophotometer. The excipients 
mixture without the drug treated in the similar manner as the niosomal suspension was used as 
blank. The drug content was calculated. 
ESTIMATION OF ENTRAPMENT EFFICIENCY100 
The entrapment efficiency of the formulations was determined by centrifuging 1 ml of 
the suspension diluted to 10 ml with distilled water at 15,000 rpm for 60 minutes at 4°C using 
a high speed cooling centrifuge in order to separate niosomes from unentrapped drug. The free 
drug concentration in the supernatant was determined at 225 nm using UV- Visible 
Spectrophotometer after suitable dilution. The percentage of drug entrapment in niosomes was 
calculated using the following formula, 
% drug entrapment = (Total drug- Drug in supernatant liquid)  X 100 
Total drug 
IN- VITRO RELEASE STUDY33, 50 
In- vitro drug release pattern was studied using dialysis membrane. The niosomal 
preparation  after separation of unentrapped drug was placed in an open ended glass tube, one 
end of which was tied with the dialysis membrane. This acted as the donor compartment. 
Then the open ended tube was placed in a beaker containing 100 ml phosphate buffered 
saline pH 7.4, which acted as receptor compartment. The temperature of the receptor medium 
was maintained at 37°±2°C and the medium was agitated at a speed of 100 rpm using a 
magnetic stirrer. 
5 ml of the samples were collected at a predetermined time and replenished 
immediately with the same volume of fresh buffer PBS pH 7.4. The sink condition was 
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maintained throughout the experiment. The collected samples were analyzed 
Spectrophotometrically at 225 nm using UV- Visible spectrophotometer. 
KINETICS OF DRUG RELEASE100,131 
To study the kinetics and mechanism of drug release, the release data of the in- vitro 
dissolution study of niosomes were fitted in various kinetic models. 
 Zero order equation 
The zero order release kinetics can be obtained by plotting cumulative percentage 
of drug release Vs time (hours). It is ideal for the formulation to have release profile of 
zero order to achieve pharmacological prolonged action. 
C= K0t 
Where, K0= Zero order constant in conc/ time 
  t= time in hours 
 First order equation 
The graph was plotted as log % cumulative drug remaining Vs time in hours. 
Log C= Log C0- Kt/ 2.303 
Where, C0= Initial drug concentration 
 K= First order constant 
 T= Time in hours 
 Higuchi kinetics 
The graph was plotted with % cumulative drug released Vs square root of time. 
Q= Kt1/2 
Where, K= constant reflecting design variable system (Differential rate constant) 
 T= time in hours 
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The release rate of the drug is inversely proportional to the square root of time and 
is related to the rate of drug diffusion. 
 Hixson and Crowell erosion equation 
To evaluate the drug release with changes in the surface area and the diameter of 
particles, the data were plotted using the Hixson and Crowell erosion equation. The graph 
was plotted by cube root of % drug remaining Vs Time in hours. 
Q01/3- Qt1/3= KHC X t 
Where, Qt= amount of drug released at time t 
 Q0= initial amount of drug 
KHC= rate constant for Hixson Crowell equation 
 Korsmeyer- Peppas equation 
To evaluate the mechanism of drug release, it was further plotted in Peppas 
equation as log cumulative % of drug released Vs log time. 
Mt/ Mα= Ktn 
Where, Mt/ Mα= fraction of drug released at time t 
 T= release time 
 K= release rate constant 
 n= diffusional exponent indicative of the mechanism of drug release. 
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The diffusion mechanism is given by the slope (n) value, 
n value Mechanism 
0.45 Fickian diffusion 
0.45<n<0.89 Anamolous or non- Fickian diffusion 
0.89 Case- II transport 
n> 0.89 Super case- II transport 
 
The models were used to analyze the release of pharmaceutical polymeric dosage forms 
when the release mechanism was not known or more than one type of release was involved. 
The r2 and K values were calculated for the linear curve obtained by regression analysis of the 
above plots. 
SCANNING ELECTRON MICROSCOPY50, 132 
 The sizes of the vesicles were measured by scanning electron microscope 
(HITACHI S- 150). A small amount of sample of niosomes suspension was taken in cover slip 
on the specimen stub. It was coated with carbon and then with gold vapour using Hitachi 
vacuum evaporator, model HITACHI S 5 GB. The samples were examined under scanning 
electron microscope, which is operated at 15 kilovolts and then photographed. 
ZETA POTENTIAL ANALYSIS46 
Zeta potential analysis was used to measure the stability of niosome by studying its 
colloidal property. Aggregation is attributed to the shielding of the vesicle surface charge by 
ions in solution and thereby reducing the electrostatic repulsion. Vesicle surface charge can be 
estimated by measurement of particle electrophoretic mobility and is expressed as the Zeta 
potential. The study was conducted using Malvern Zeta Analyzer. 
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FORMULATION OF NIOSOME ENTRAPPED KETOCONAZOLE GEL50 
The Promising niosomal suspension ,( formulation of niosomes prepared using the 
optimized ratio of surfactants) containing ketoconazole equivalent to 2% w/w was 
incorporated into the gel base composed of Carbopol 940 (1.5%), Glycerol (10%), 
Triethanolamine (q.s.) and distilled water up to 15g. 
EVALUATION OF NIOSOMAL GEL50 
Physical Appearance 
The prepared gel was examined for clarity, color, homogeneity and the presence of foreign 
particles. 
pH 
2.5g of gel was accurately weighed and dispersed in 25 ml of distilled water. The pH of the 
dispersion was measured by using a digital pH meter. 
Rheological study 
Viscosity measurement:  
Viscosity was determined by Brookfield programmable DV III ultra viscometer. In the 
present study, spindle no. CP 52 with an optimum speed of 0.01 rpm was used to measure 
the viscosity of the preparation. 
Content Uniformity: 50   
The drug content of the prepared gel was carried out by dissolving accurately weighed 
quantity of gel equivalent to 10mg of the drug in 100 ml volumetric flask and suitable 
volume of 50% n-propanol for lysis of the vesicles. The volume was made up to 100 ml 
with methanol. The content was filtered through Whatman filter paper No.41. 5 ml of above 
solution was taken into a 50ml volumetric flask and volume was made upto mark with 
methanol. The content of Ketoconazole was determined at 225 nm against blank by using 
the Shimadzu UV/visible spectrophotometer. 
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Estimation of entrapment efficiency100 
The entrapment efficiency of the formulations was determined by centrifuging 0.5 g of 
the gel equivalent to 10mg of ketoconazole diluted to 10 ml with distilled water at 15,000 rpm 
for 60 minutes at 4°C using a high speed cooling centrifuge in order to separate niosomes from 
unentrapped drug. The free drug concentration in the supernatant was determined at 225 nm 
using UV- Visible Spectrophotometer after suitable dilution. The percentage of drug 
entrapment in niosomes was calculated using the following formula, 
% drug entrapment = (Total drug- Drug in supernatant liquid)  X 100 
Total drug 
In-vitro Drug Diffusion study33 
  In- vitro drug diffusion study was studied using dialysis membrane. The niosomal 
gel equivalent to 10mg of the drug was placed in an open ended glass tube, one end of which 
was tied with the dialysis membrane. This acted as the donor compartment. Then the open 
ended tube was placed in a beaker containing 100 ml phosphate buffered saline pH 7.4, 
which acted as receptor compartment. The temperature of the receptor medium was 
maintained at 37°±2°C and the medium was agitated at a speed of 100 rpm using a magnetic 
stirrer. 
5 ml of the samples were collected at a predetermined time and replenished 
immediately with the same volume of fresh buffer PBS pH 7.4. The sink condition was 
maintained throughout the experiment. The collected samples were analyzed 
Spectrophotometrically at 225 nm using UV- Visible spectrophotometer. 
  STABILITY STUDIES25, 100 
The stability studies of the optimized niosomal formulations were performed at 
different conditions of temperature and the effect on physical characterisitics, entrapment 
efficiency and drug content was noted. The niosomal dispersions were kept in the air tight 
containers and stored at 2- 8°C and at room temperature (30±2°C) for 30 days and 2 ml samples 
were withdrawn every 15 days and at the end of 45 days. The samples were analyzed 
spectrophotometrically at λmax 225 nm after disrupting the vesicles with 50% n-propanol. 
9. RESULTS AND DISCUSSIONS 
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DRUG EXCIPIENT COMPATIBILITY STUDIES 
The possibilities of drug- excipient (cholesterol, nonionic surfactant) interactions 
were investigated by recording the FT- IR spectrum. The FT- IR spectra of the drug and the 
formulations KTZ 20-3, KTZ 40-4 and KTZ 60-5 are shown in figures, tables.  
FT- IR SPECTRA OF KETOCONAZOLE AND THE NIOSOMAL FORMULATIONS 
Fig. 17: FT- IR spectra of Ketoconazole 
 
Table 4: Interpretation: 
S.No. WAVE NUMBER (cm-1) CHARACTERISTICS 
1 2884 -CH stretching(Aliphatic) 
2 1459 -CH bending (Aliphatic) 
3 3056 -C- H stretching(Aromatic) 
4 1720 -C=O stretching (ketone) 
5 735 
-C-Cl stretching (substituted 
Chloride) 
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Fig. 18:  FT- IR spectra of Ketoconazole with Span 20 
 
Table 5: Interpretation: 
S.No. WAVE NUMBER (cm-1) CHARACTERISTICS 
1 2881 -CH stretching(Aliphatic) 
2 1456 -CH bending (Aliphatic) 
3 3056 -C- H stretching(Aromatic) 
4 1721 -C=O stretching (ketone) 
5 737 
-C-Cl stretching (substituted 
Chloride) 
 
It is confirmed that there is no major shifting as well as loss of functional peaks 
between the spectra of drug and drug loaded niosomes. 
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Fig. 19: FT- IR spectra of Ketoconazole with Span 40 
 
Table 6: Interpretation: 
S.No. WAVE NUMBER (cm-1) CHARACTERISTICS 
1 2891 -CH stretching(Aliphatic) 
2 1457 -CH bending (Aliphatic) 
3 3042 -C- H stretching(Aromatic) 
4 1723 -C=O stretching (ketone) 
5 736 
-C-Cl stretching (substituted 
Chloride) 
 
It is confirmed that there is no major shifting as well as loss of functional peaks 
between the spectra of drug and drug loaded niosomes. 
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Fig. 20: FT- IR spectra of Ketoconazole with Span 60 
 
Table 7: Interpretation: 
S.No. WAVE NUMBER (cm-1) CHARACTERISTICS 
1 2925 -CH stretching(Aliphatic) 
2 1457 -CH bending (Aliphatic) 
3 3042 -C- H stretching(Aromatic) 
4 1732 -C=O stretching (ketone) 
5 736 
-C-Cl stretching (substituted 
Chloride) 
 
It is confirmed that there is no major shifting as well as loss of functional peaks 
between the spectra of drug and drug loaded niosomes. 
 
 
 
 
Results and Discussions… 
 
Department of Pharmaceutics, COP, MMC Page 103 
 
STANDARD CURVE FOR KETOCONAZOLE50 
The UV Spectrophotometric method was used to analyze Ketoconazole. The 
absorbance of the drug in phosphate buffered saline pH 7.4 with small amount of methanol 
was measured at a wavelength of 225 nm. The results are given in Table and Figure 
Table 8: Data for Calibration Curve of Ketoconazole 
S. No. Concentration (µg/ ml) Absorbance at 286 nm 
1 2 0.083 ± 0.0180 
2 4 0.200 ± 0.0314 
3 6 0.303 ± 0.035 
4 8 0.409 ± 0.0396 
5 10 0.506 ± 0.0467 
*Mean± SD (n=3) 
Fig 21: Standard Curve of Ketoconazole in PBS pH 7.4 
 
 The standard curve of Ketoconazole in PBS pH 7.4 was linear in 2 to 10 mcg/ ml 
concentrations, starting from origin. The curve obeys Beer Lambert’s law. 
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OPTIMIZATION OF PROCESS RELATED VARIABLES 
 Effect of hydration time  
Table 9: Effect of Hydration Time On Entrapment Efficiency 
S. No. Hydration Time (minutes) Entrapment Efficiency (%w/w) 
1 30 31.06 ± 2.52 
2 45 39.5 ±1.15 
3 60 75.2 ± 0.16 
4 75 73.53 ± 1.5 
5 90 71.27 ±1.11 
 *Mean± SD (n=3) 
The niosomal formulations were hydrated with 20 ml of distilled water for 30, 45, 
60, 75 and 90 minutes. The parameters like vesicle formation and entrapment efficiency 
was studied. The results indicated that vesicles were not formed properly but resulted in 
aggregates with hydration time of 30 minutes. On increase in hydration time, the spherical 
vesicles were formed and the entrapment efficiency also increased with increase in 
hydration time from 30 minutes to 60 minutes. Further increase in the hydration time to 90 
minutes did not produce any great impact on the entrapment efficiency100 
 
 Effect of capacity and rotational speed of evaporator flask100 
Thin film was not formed with 50 ml evaporator flask, and the resulting suspension 
was not uniform. The procedure was repeated with 1000ml evaporator flask. The thickness 
and uniformity of the film depended on the rotational speed of the flask. A speed of 100 
rpm produced a uniform thin film which on hydration produced spherical vesicles. Lower 
speed (50 rpm) resulted in a non- uniform film and higher speed (150 rpm) produced thick 
film which on hydration formed aggregates of vesicles. Optimum rotational speed for 
formation of uniform thin film in a 1000ml flask was found to be 100 rpm initially, which 
is increased to 150 rpm when 80 % of the solvent has evaporated. 
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 Effect of Sonication time100 
Table. 10: 
S. No. Sonication  Time (minutes) Entrapment Efficiency (%w/w) 
1 0 46.06 ± 0.124 
2 05 51.13 ±0.016 
3 10 60.15 ± 0.040 
4 15 57.20 ± 0.081 
5 20 55.20 ±1.11 
*Mean± SD (n=3) 
 
Formulations were sonicated three times for 5 minutes with 2 sec running time and 1 sec 
interval. Spherical vesicles were not observed after 10 minutes of sonication. The 
entrapment efficiency decreased as sonication time increased above 10 minutes. Exposure 
to Ultrasound for more than 10 minutes damages the vesicles. 10 minutes of sonication 
resulted in uniform unilamellar vesicles. 
 Effect of Osmotic shock100 
The niosomal formulations were treated with hypotonic (0.5% NaCl), hypertonic 
(1.6% NaCl) and isotonic saline (0.9% NaCl). The effect of osmotic shock is shown in 
figure.  
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Fig. 22: Effect of Osmotic Shock 
a.Hypertonic (1.6% NaCl)   b.Hypotonic (0.5% NaCl) 
 
 
 
      c. Isotonic saline (0.9% NaCl)  
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CHARACTERIZATION OF NIOSOMES 
 Drug content and Entrapment Efficiency 
Table 11: Drug Content and Entrapment Efficiency of Ketoconazole Niosomes 
FORMULATION 
CODE 
% DRUG CONTENT 
(% w/w) 
% ENTRAPMENT 
EFFICIENCY 
(% w/w) 
KTZ 20 – 1 94.64 41.7 
KTZ 20 – 2 93.41 52.1 
KTZ 20 – 3 95.22 56.1 
KTZ 20 – 4 91.73 46.2 
KTZ 20 – 5 97.70 43.2 
KTZ 40 – 1 94.06 51.7 
KTZ 40 – 2 87.61 59.1 
KTZ 40 – 3 95.37 65.3 
 KTZ 40 – 4 88.81 72.3 
KTZ 40 – 5 92.31 69.2 
KTZ 60 – 1 98.44 51.8 
KTZ 60 – 2 97.57 52.8 
KTZ 60 – 3 95.81 56.21 
KTZ 60 – 4 94.64 56.6 
KTZ 60 – 5 99.6 60.2 
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Fig. 23: Drug Content of Ketoconazole Niosomes 
 
Fig. 24: Entrapment Efficiency of Ketoconazole Niosomes 
 
 
 
 
 
 
 
The entrapment efficiency of the formulations was observed to be between 41.7% and 72.1%. 
The entrapment efficiency was found to be 56.1%, 72.3% and 60.2% for the formulations 
KTZ 20-3, KTZ 40-4 and KTZ 60-5.  
The highest entrapment efficiency was observed with Span 40 formulation followed by 
Span 60 niosomes in the similar range. This may be due to the higher HLB value of Span 40 
compared to Span 60. The entrapment efficiency decreased as the HLB value decreased from 
6.7 of Span 40 to 4.7 of Span 60.15Eventhough, Span 20 has a HLB value of 8.6 the entrapment 
efficiency of the SPAN 20 formulations was observed to be less than the other two 
formulations. This may be due to the difference in phase transition temperature.36,132. The order 
of non -ionic surfactants that resulted in better entrapment efficiency is as follows: 
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IN- VITRO RELEASE STUDY33 
The in- vitro release study of Ketoconazole niosomes was done using dialysis 
membrane in an open ended tube- beaker assembly using phosphate buffered saline (PBS) pH 
7.4 with 10% methanol as the diffusion medium. The results are shown in Tables and figures 
Table 12: In- vitro release of niosomes containing Span 20 in different ratios 
Time 
(in hours) 
Cumulative % Drug Release (% w/w) 
Pure Drug KTZ 20-1 KTZ 20-2 KTZ 20-3 KTZ 20-4 KTZ 20-5 
0 0 0 0 0 0 0 
1 10.14 7.21 7.42 9.31 7.10 9.48 
2 33.72 10.49 11.50 12.85 10.30 13.20 
3 48.98 17.66 14.54 15.16 15.77 16.76 
4 62.32 23.61 18.31 18.12 20.07 19.69 
5 72.21 27.92 21.00 22.32 25.25 22.01 
6 88.45 30.71 23.17 27.48 28.52 25.82 
7 94.14 33.57 26.02 34.65 31.90 27.64 
8 98.32 36.51 28.34 37.27 35.38 30.93 
9  41.05 32.58 41.75 38.25 36.46 
10  44.98 36.35 45.72 41.20 39.35 
11  49.02 40.87 48.39 44.22 42.31 
12  51.65 43.06 52.56 48.73 45.34 
24  65.77 69.43 82.21 73.99 64.14 
 
The cumulative % drug release at 24 hours increased initially with 65.77% for KTZ 
20-1, 69.43% for KTZ 20-2 and 82.21% for KTZ 20-3; after which the release decreased 
gradually for the next higher surfactant ratios with 73.99% for KTZ 20- 4 and 64.14% for KTZ 
20- 5. 
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Table 13: In- vitro release of niosomes containing Span 40 in different ratios 
Time 
(in 
hours) 
Cumulative % Drug Release 
Pure Drug KTZ 40- 1 KTZ 40- 2 KTZ 40- 3 KTZ 40- 4 KTZ 40- 5 
0 0 0 0 0 0 0 
1 10.14 5.85 8.86 7.83 7.59 6.74 
2 33.72 9.56 11.33 12.47 11.62 11.64 
3 48.98 11.26 13.63 16.46 15.47 14.56 
4 62.32 12.41 16.01 18.20 20.42 17.60 
5 72.21 17.30 21.13 22.41 26.56 20.29 
6 88.45 23.03 22.29 27.75 30.94 23.54 
7 94.14 32.72 26.16 31.38 33.29 26.44 
8 98.32 37.89 30.17 34.16 35.16 28.49 
9  40.77 32.59 38.46 38.47 34.36 
10  44.95 34.48 43.39 43.28 40.46 
11  49.90 36.40 46.56 45.43 43.50 
12  52.38 40.09 49.80 48.55 47.08 
24  72.97 74.72 72.58 82.69 70.32 
 
The cumulative % drug release at 24 hours for the Span 40 series is 72.97% for KTZ 
40 - 1 whereas it is 74.72%, 72.58%, 82.69% and 7.96% for formulations KTZ 40 - 2, KTZ 40 
– 3, KTZ 40 – 4,  KTZ 40 - 5 respectively. 
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Table 14: In- vitro release of niosomes containing Span 60 in different ratios 
Time 
(in 
hours) 
Cumulative % Drug Release (% w/w) 
Pure 
Drug 
KTZ 60- 1 KTZ 60-2 KTZ 60- 3 KTZ 60-4 KTZ 60- 5 
0 0 0 0 0 0 0 
1 10.14 6.74 5.52 4.72 4.74 6.67 
2 33.72 10.99 10.91 8.61 8.65 10.87 
3 48.98 13.24 12.48 12.94 12.45 14.41 
4 62.32 18.18 14.82 16.35 15.28 18.60 
5 72.21 22.32 16.07 20.46 20.48 21.46 
6 88.45 23.92 24.37 25.30 23.10 23.42 
7 94.14 31.46 27.21 28.65 32.54 26.43 
8 98.32 34.59 30.72 32.68 34.54 30.55 
9  37.81 33.76 39.08 38.25 32.81 
10  40.53 37.47 46.29 40.94 34.62 
11  43.90 40.71 48.75 43.14 37.45 
12  47.95 44.05 51.24 46.48 41.37 
24  57.45 63.25 76.68 63.96 58.47 
 
The cumulative % drug release of Span 60 niosomes at 24 hours was observed to be 
increasing in the order as follows; 57.45% for KTZ 60-1, 63.25% for KTZ 60-2 and 76.68% 
for KTZ 60-3 respectively, after which the cumulative % drug release decreased gradually with 
63.96% for KTZ 60-4 and 58.47% for KTZ 60-5 respectively. 
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Fig. 25: In- vitro release of niosomes containing Span 20 in different ratios 
 
 
 
 
 
 
 
 
 
 
Fig. 26: In- vitro release of niosomes containing Span 40 in different ratios 
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Fig. 27: In- vitro release of niosomes containing Span 60 in different ratios 
 
 
Fig. 28: Comparison of in- vitro release of niosomes with highest entrapment efficiency 
 
All the niosomal formulations showed sustained release when compared with pure 
drug. 
  The cumulative % drug release at 24 hours for different ratios of the three non- 
ionic surfactants was in the following order: 
 
Span 20: KTZ 20- 1 < KTZ 20- 2 < KTZ 20- 3 > KTZ 20- 4 > KTZ 20- 5 
Span 40: KTZ 40- 1 < KTZ 40- 2 > KTZ 40- 3 < KTZ 40- 4 > KTZ 40- 5 
Span 60: KTZ 60- 1 < KTZ 60 -2 < KTZ 60 – 3 > KTZ 60 -4 < KTZ 60 - 5 
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KINETICS OF DRUG RELEASE 
The in- vitro release data was applied to various kinetic models to predict the 
mechanism of drug release of the niosomal formulations prepared with different non ionic 
surfactants.  
Release Kinetics of Formulation KTZ 20-3 
Fig. 29: Zero- Order Release Kinetics of KTZ 20-3 
 
Fig. 30: First Order Release Kinetics of KTZ 20-3 
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Fig. 31: Higuchi Model Kinetics of KTZ 20-3 
 
Fig. 32: Hixon Crowell Model Kinetics of KTZ 20-3 
 
Fig. 33: Korsemeyer- Peppas Model Kinetics of KTZ 20-3 
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Release Kinetics of Formulation KTZ 40-4 
Fig. 34: Zero Order Release Kinetics of KTZ 40-4 
 
Fig. 35: First Order Release Kinetics of KTZ 40-4 
 
Fig. 36: Higuchi Model Kinetics of KTZ 40-4 
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Fig. 37: Hixon Crowell Kinetics of KTZ 40-4 
 
Fig. 38: Korsemeyer- Peppas Model Kinetics of KTZ 40-4 
 
Release Kinetics of Formulation KTZ 60-5 
 
Fig. 39: Zero- Order Release Kinetics of KTZ 60-5 
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Fig. 40: First Order Release Kinetics of KTZ 60-5 
 
Fig. 41: Higuchi Model Kinetics of KTZ 60-5 
 
Fig. 42: Hixon Crowell Model Kinetics of KTZ 60-5 
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Fig. 43: Korsemeyer- Peppas Release Kinetics of KTZ 60-5 
 
 
The regression coefficient (r2) was determined using the drug release data. The results are shown 
in Table. 
Table 15: Drug Release Kinetics 
FORMULATION 
CODE 
ZERO 
ORDER 
FIRST 
ORDER 
HIGUCHI 
MODEL 
KORSEMEYER 
PEPPAS 
HIXSON 
CROWELL 
R2 R2 R2 R2 N R2 
KTZ 20-3 0.966 0.985 0.949 0.975 0.750 0.996 
KTZ 40-4 0.976 0.970 0.956 0.994 0.771 0.993 
KTZ 60-5 0.950 0.991 0.936 0.990 0.937 0.989 
All the formulations followed first- order kinetics and their R2 value lied between 0.970 
and 0.991 indicating the release to be dose dependent. 
 The drug release was proportional to the square root of time indicating that Ketoconazole 
release from niosomes was diffusion controlled. 
 The n value for the Korsemeyer- Peppas model for Ketoconazole niosomal formulation 
was found to be between 0.750 and 0.937 which confirms the anomalous Non- Fickian 
type diffusion and Super case-II report. 
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 The drug release pattern from Ketoconazole loaded niosomes follows Korsemeyer- 
Peppas model, Higuchi model and first order release. 
PARTICLE SIZE ANALYSIS 
Fig. 44: Particle Size of Formulation KTZ 20-3 
 
 The average particle size of KTZ 20-3 formulation was found to be 260.1nm.. 
Fig. 45: Particle Size of Formulation KTZ 40-4 
 
 The average particle size of KTZ 40-4 formulation was found to be 272.3 nm 
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Fig. 46: Particle Size of Formulation KTZ 60-5
 
 
 The average particle size of KTZ 60-5 formulation was found to be 226.3 nm. 
/ The average vesicle sizes of the Ketoconazole Niosomes are in the order 
Span 40 > Span 20 > Span 60 
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SCANNING ELECTRON MICROSCOPY  
 The SEM images were seen for the optimized niosomal formulations. The results are 
shown in the following figures. 
Fig. 47: SCANNING ELECTRON MICROSCOPIC IMAGES OF KETOCONAZOLE 
NIOSOMES 
a) Span 20 (KTZ 20-3)                                                           b) Span 60 (KTZ 40-4)  
 
c) Span 60 niosomes (KTZ 60-5) 
 
The SEM analysis showed that the optimized niosomal formulations were discrete and 
spherical in shape. 
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FORMULATION OF KETOCONAZOLE NIOSOMAL GEL 
Ketoconazole niosomal gel formulations with the optimized ratio of the surfactants were 
prepared with Carbopol 940 as gelling agent which is due to its hydrophilic nature and bio-
adhesive properties, which may result in an increased residence time of drug at the site of 
absorption by interacting with the mucosa.  The formed gel formulations were evaluated for 
appearance, pH, viscosity, drug content, and in-vitro drug diffusion study. 
 Physical appearance:  
The formed gel is off-white in color. It is little bit sticky in nature.  
 pH:  
The pH of the gel formulations were found to be in the range of 6.7 to 6.9. It is mentioned in 
the table 15. 
Table 15: pH of the different Niosomal gel formulations.  
S.no Formulation code  pH 
01. KTZ 20-3 6.59 
02. KTZ 40-4 6.72 
03. KTZ 60-5 6.74 
 
 Viscosity: 
The viscosity of the gel formulations were mentioned in the table 16. 
Table 16: Viscosity of the gel formulations. 
S.no Formulation code Viscosity (cps) 
01. KTZ 20-3 8320 
02. KTZ 40-4 8256 
03. KTZ 60-5 8675 
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 Drug content analysis: 
The percentage drug content of the formulations were mentioned in the table as follows; 
Table 17: % Drug content of the different gel formulations. 
S.no Formulation code % Drug content (%w/w) 
01. KTZ 20-3 98.13 
02. KTZ 40-4 96.10 
03. KTZ 60-5 94.3 
 Entrapment Efficiency: 
The entrapment efficiency of the different gel formulations are as follows; 
Table 18: Entrapment Efficiency of the different gel formulations 
S.no Formulation code % entrapment (%w/w) 
01. KTZ 20-3 52.4 
02. KTZ 40-4 63.8 
03. KTZ 60-5 65.2 
The highest entrapment efficiency was observed with KTZ 60-5 formulation. This may be due 
to the higher phase transition temperature of Span 60.100,132  
 In-vitro Drug Diffusion studies: 
The in-vitro drug diffusion study of Ketoconazole niosomal gel was done using dialysis 
membrane in an open ended tube-beaker assembly using phosphate buffered saline (PBS) pH 
7.4 as the diffusion medium. The results are shown in tables and figures.  
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Table 19: In-vitro release of Ketoconazole niosomal gel in the optimized ratio of 
surfactants. 
Time 
(Hours) 
Cumulative % Drug release 
Plain Ketoconazole 
Gel 
KTZ 20-3 KTZ 40-4 KTZ 60-5 Phytoral 
0 0 0 0 0 0 
1 5.96 2.08 2.28 2.47 6 
2 8.9 2.7 5.91 6.6 15.1 
3 15.97 3.63 10.2 11.65 22.84 
4 19.73 5.8 13.29 15.81 28.73 
5 22.84 6.87 17.71 18.95 34.66 
6 25.86 7.58 20.92 20.81 40.82 
7 28.78 8.11 23.45 23.72 46.81 
8 34.79 11.85 25.06 27.93 50.81 
9 40.84 14.76 26.96 30.7 54.71 
10 45.72 16.79 28.78 33.75 58.9 
11 47.76 19.09 30.9 37.89 62.79 
12 49.81 21.37 32.67 41.77 66.76 
24 60.87 28.72 43.87 50.77 81.61 
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Figure.48. In-vitro Drug diffusion study of Ketoconazole Niosomal gel.  
 
 
 
 
 
 
 
The cumulative percentage release for the plain ketoconazole gel, marketed ointment, 
niosomal gel preparations at the end of 24 hours were plain gel -60.87, phytoral-81.61, 
KTZ 20-3 -28.72, KTZ 40-4-43.87, KTZ 60-5 – 50.77 respectively. The niosomal gel 
preparations showed prolonged release at the end of 24 hours.  
KINETICS OF DRUG RELEASE 
The in- vitro release data was applied to various kinetic models to predict the 
mechanism of drug release of the niosomal gel formulations prepared with different non ionic 
surfactants.  
Release Kinetics of Formulation KTZ 20-3 gel 
Fig. 49: Zero- Order Release Kinetics of KTZ 20-3. 
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Fig. 50: First Order Release Kinetics of KTZ 20-3 
 
Fig. 51: Higuchi Model Kinetics of KTZ 20-3 
 
Fig. 52: Hixon Crowell Model Kinetics of KTZ 20-3 
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Fig. 53: Korsemeyer- Peppas Model Kinetics of KTZ 20-3  
 
 
Release Kinetics of Formulation KTZ 40-4 gel 
Fig. 54: Zero Order Release Kinetics of KTZ 40-4 
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Fig. 55: First Order Release Kinetics of KTZ 40-4 
 
 
 
Fig. 56: Higuchi Model Kinetics of KTZ 40-4 
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Fig. 57: Hixon Crowell Kinetics of KTZ 40-4 
 
 
 
 
Fig. 58: Korsemeyer- Peppas Model Kinetics of KTZ 40-4 
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Release Kinetics of Formulation KTZ 60-5 gel 
 
Fig. 59: Zero- Order Release Kinetics of KTZ 60-5 
 
 
 
Fig. 60: First Order Release Kinetics of KTZ 60-5 
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Fig. 61: Higuchi Model Kinetics of KTZ 60-5 
 
 
Fig. 62: Hixon Crowell Model Kinetics of KTZ 60-5 
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Fig. 63: Korsemeyer- Peppas Release Kinetics of KTZ 60-5 
 
The regression coefficient (r2) was determined using the drug release data. The results are shown 
in Table. 
Table 20: Drug Release Kinetics 
FORMULATION 
CODE 
ZERO 
ORDER 
FIRST 
ORDER 
HIGUCHI 
MODEL 
KORSEMEYER 
PEPPAS 
HIXSON 
CROWELL 
R2 R2 R2 R2 N R2 
KTZ 20-3 0.929 0.938 0.889 0.954 0.958 0.933 
KTZ 40-4 0.878 0.929 0.963 0.95 0.947 0.915 
KTZ 60-5 0.877 0.926 0.946 0.956 0.976 0.912 
All the formulations followed first- order kinetics and their R2 value lied between 0.926 
and 0.938 indicating the release to be dose dependent. 
 The drug release was proportional to the square root of time indicating that Ketoconazole 
release from niosomes was diffusion controlled. 
 The n value for the Korsemeyer- Peppas model for Ketoconazole niosomal formulation 
was found to be between 0.947 and 0.976 which confirms the Super case-II transport. 
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 The drug release pattern from Ketoconazole loaded niosomal gel follows Korsemeyer- 
Peppas model, Higuchi model and first order release. 
STABILITY STUDIES OF KETOCONAZOLE NIOSOMAL GEL 50,100 
 Stability studies of the ketoconazole gel formulations (KTZ 20-3, KTZ 40-4, KTZ 60-5) 
were carried out by storing at 4°C - 8°C (refrigeration temperature) and 25°C ±2°C for a 
period of 45 days as per ICH (International Conference on Harmonization) guidelines. 
Table 21: Stability study of ketoconazole niosomal gel formulation KTZ 20-3 at 
different temperature. 
Time 
of 
storage 
in days 
Temperature of storage 
Drug Content (%) 
4°C - 8°C 
(refrigeration 
temperature) 
Entrapment 
efficiency (%) 
4°C - 8°C 
(refrigeration 
temperature) 
Drug Content (%) 
25°C ±2°C 
( room temperature) 
Entrapment 
efficiency (%) 
25°C ±2°C 
( room 
temperature) 
0 98.13 52.4 98.13 52.4 
15 98.04 50.1 94.94 47.5 
30 97.84 49.6 92.8 46.3 
45 97.6 49.3 91.8 45.9 
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Table 22: Stability study of ketoconazole niosomal gel formulation KTZ 40-4 at 
different temperature. 
Time 
of 
storage 
in days 
Temperature of storage 
Drug Content (%) 
4°C - 8°C 
(refrigeration 
temperature) 
Entrapment 
efficiency (%) 
4°C - 8°C 
(refrigeration 
temperature) 
Drug Content (%) 
25°C ±2°C 
( room temperature) 
Entrapment 
efficiency (%) 
25°C ±2°C 
( room 
temperature) 
0 96.10 63.8 96.10 63.8 
15 95.90 63.5 95.10 63.0 
30 95.71 63.2 94.16 62.0 
45 995.32 63.0 93.58 61.4 
 
Table 23: Stability study of ketoconazole niosomal gel formulation KTZ 60-5 at 
different temperature. 
Time 
of 
storage 
in days 
Temperature of storage 
Drug Content (%) 
4°C - 8°C 
(refrigeration 
temperature) 
Entrapment 
efficiency (%) 
4°C - 8°C 
(refrigeration 
temperature) 
Drug Content (%) 
25°C ±2°C 
( room temperature) 
Entrapment 
efficiency (%) 
25°C ±2°C 
( room 
temperature) 
0 94.30 65.2 94.30 65.2 
15 94.10 64.7 93.19 64.3 
30 93.97 64.2 92.22 63.1 
45 93.3 63.1 91.06 62.0 
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 The entrapment efficiency of the drug in the niosomal gel was estimated immediately after the 
preparation and after every 15 days for 45 days . The drug leakage from the vesicles was least 
at 4°C. this may be attributed to phase transition of surfactant and lipid causing leakage of 
vesicles occurs at higher temperature at storage. Hence, the niosomes can be stored at 4-8°C. 
The improved stability of niosomes after incorporation into the gel base may be due to 
prevention of fusion of niosomes. The higher drug skin retention in case of niosomal gel maybe 
due to creation of reservoir effect of drug in the skin and thereby increasing the drug retention 
capacity into the skin.50    
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 The purpose of this research was to prepare Ketoconazole loaded niosomes for sustained 
release of drug and incorporate it in to topical gel delivery system to reduce the side effects 
by site specific targeting. 
 Thin film hydration technique was employed to produce niosomes using non ionic 
surfactants and cholesterol. 
 The process related parameters were optimized such as hydration time (60 minutes), 
sonication time (10minutes), osmotic shock, rotational speed of the evaporator flask 
(initially 100 rpm, later 150 rpm). 
 Cholesterol used as a membrane additive, acts as a stabilizer as well as fluidity buffer to 
improve the stability of the vesicles. 
 The formulations were prepared using different non- ionic surfactants by varying the 
surfactant concentration (Span 20, Span 40 and Span 60) and keeping the cholesterol 
concentration fixed. 
 The formulated niosomes were characterized for entrapment efficiency. 
 The order of entrapment efficiency of the formulations are as follows; 
SPAN 40 > SPAN 60 > SPAN 20 
 The order of in- vitro release of the formulations are as follows: 
SPAN 40 > SPAN 20 > SPAN 60 
 The drug release pattern from Ketoconazole loaded niosomes follows Higuchi’s model 
First order of release and Korsemeyer Peppas release. 
 The average particle size of the formulated Ketoconazole niosomes exhibited around 260 
nm. 
 SEM analysis of the niosomal dispersion showed the spherical shape of the vesicles. 
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 The results of the FT- IR studies proved that there is no interaction between the drug, 
cholesterol and the non-ionic surfactants. 
 The optimized Niosomal dispersion were further formulated as topical gel delivery sysem. 
 The formulated niosomal gel was characterized for the physical appearance, pH and 
rheological behavior. 
 The formulated niosomal gel was evaluated for drug content and in-vitro diffusion studies 
were carried out using open ended diffusion tube. 
 The order of in- vitro release of the  niosomal gel formulations are as follows: 
SPAN 60 > SPAN 40 > SPAN 20. 
 The drug release pattern from Ketoconazole loaded niosomal gel follows Higuchi’s model 
First order of release and Korsemeyer Peppas release. 
 From the stability studies, the optimum storage condition for the  niosomal gel formulations 
was found to be 4-8°C 
 It is concluded that the thin film hydration technique is a useful method for the successful 
incorporation of poorly water soluble drug Ketoconazole into niosomes with high 
entrapment efficiency. The prolonged release of the drug from the niosome suggests that 
the frequency of administration and adverse effects significantly thereby improving the 
patient compliance. The administration of drug as gel type formulation enhances its 
penetration across the stratum corneum and the reduced size and its vesicular structure not 
only improved its localization in the stratum spinosum in which the infected macrophages 
reside and also its uptake by the infected macrophages. 
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